metformin has been researched along with Diabetes Mellitus, Type 1 in 231 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Diabetes Mellitus, Type 1: A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Metformin showed favourable effect on GV in overweight/obese T1DM patients and reduction in systolic blood pressure, TDD insulin, fasting venous glucose and fructosamine." | 9.69 | Effects of metformin on glycaemic variability in combination with insulin in overweight/obese patients with type 1 diabetes. ( Adam, NLB; Chin Voon, T; Long Bidin, MBB; Poh Shean, W, 2023) |
| " Whether metformin improves hepatic, muscle or adipose tissue insulin sensitivity has not been studied in adults with Type 1 diabetes." | 9.41 | Insulin resistance in type 1 diabetes managed with metformin (INTIMET): Study protocol of a double-blind placebo-controlled, randomised trial. ( Bruce, C; Evans, J; Greenfield, JR; Holmes-Walker, DJ; Kowalski, G; Liu, Z; Samocha-Bonet, D; Snaith, JR, 2021) |
| "Measure peripheral, hepatic, and adipose insulin sensitivity before and after metformin or placebo therapy in youth with obesity with type 1 diabetes." | 9.30 | Metformin Improves Peripheral Insulin Sensitivity in Youth With Type 1 Diabetes. ( Bergman, BC; Cengiz, E; Cree-Green, M; Fox, LA; Hannon, TS; Kahn, D; Libman, I; Miller, K; Nadeau, KJ; Nathan, B; Pyle, L; Tansey, M; Tichy, E; Tsalikian, E, 2019) |
| "To improve insulin sensitivity, insulin-sensitizing drugs such as metformin are commonly used in overweight and obese T1D patients." | 9.24 | A pilot study of D-chiro-inositol plus folic acid in overweight patients with type 1 diabetes. ( Defeudis, G; Del Toro, R; Fioriti, E; Guglielmi, C; Kyanvash, S; Maggi, D; Manfrini, S; Maurizi, AR; Menduni, M; Pantano, AL; Pozzilli, P, 2017) |
| "The present study is the first prospective clinical trial evaluating the effect of combined therapy of metformin and insulin on the pool of oxidized and glycated low‑density lipoproteins (LDL) in young patients with type 1 diabetes and concomitant obesity." | 9.17 | Metformin added to intensive insulin therapy reduces plasma levels of glycated but not oxidized low‑density lipoprotein in young patients with type 1 diabetes and obesity in comparison with insulin alone: a pilot study. ( Burchardt, P; Kaczmarek, J; Marcinkaniec, J; Naskręt, D; Tabaczewski, P; Wierusz-Wysocka, B; Wysocki, H; Zawada, A, 2013) |
| "In a randomized, double-blind, cross-over study, we investigated the effect of metformin on blood glucose control and daily insulin dose in overweight patients with Type 1 diabetes." | 9.12 | The effect of metformin on blood glucose control in overweight patients with Type 1 diabetes. ( Ahmed, AB; Khan, AS; McLoughney, CR, 2006) |
| "Adjuvant metformin can improve QOL, insulin sensitivity and glycaemic control in overweight adults with T1DM." | 9.12 | The addition of metformin in type 1 diabetes improves insulin sensitivity, diabetic control, body composition and patient well-being. ( Bascombe, LA; Holt, RI; Moon, RJ, 2007) |
| "To evaluate whether, in adolescents with type 1 diabetes, the addition of metformin to insulin and standard diabetes management results in 1) higher insulin sensitivity and 2) lower HbA1c, fasting glucose, insulin dosage (units per kilogram per day) and BMI." | 9.10 | Metformin as an adjunct therapy in adolescents with type 1 diabetes and insulin resistance: a randomized controlled trial. ( Cummings, E; Daneman, D; Finegood, D; Hamilton, J; Zdravkovic, V, 2003) |
| " The aim of this was to measure the effect of metformin (850 mg/twice daily) on insulin sensitivity." | 9.05 | Metformin improved insulin resistance in type I, insulin-dependent, diabetic patients. ( Aubertin, J; Brottier, E; Gin, H; Messerchmitt, C, 1985) |
| "Metformin is widely used for treating patients with type 2 diabetes mellitus." | 8.86 | [New clinical data with metformin therapy in patients with diabetes mellitus]. ( Jermendy, G, 2010) |
| " This study was set out to explore the molecular mechanism of metformin in the treatment of T1D insulin resistance." | 7.96 | Metformin Decreases Insulin Resistance in Type 1 Diabetes Through Regulating p53 and RAP2A in vitro and in vivo. ( Jiao, PF; Ma, XJ; Ren, GF; Xiao, LL; Yan, YS, 2020) |
| "Polycystic ovary syndrome (PCOS) is common in obese women with insulin resistant type 2 diabetes for which metformin treatment is getting established in addition to clomiphene." | 7.83 | A case of lean polycystic ovary syndrome with early stage of type 1 diabetes successfully treated with metformin. ( Hirose, T; Kitamura, M; Kumashiro, N; Rikitake, T; Saegusa, M; Shigiyama, F; Uchino, H; Usui, S, 2016) |
| "No statistically significant association of cardioprotection was found between metformin and myocardial infarct size in patients with diabetes and acute ST-segment elevation myocardial infarction." | 7.81 | Metformin and Myocardial Injury in Patients With Diabetes and ST-Segment Elevation Myocardial Infarction: A Propensity Score Matched Analysis. ( Akerman, M; Basnet, S; Kozikowski, A; Lesser, M; Makaryus, AN; Pekmezaris, R; Wolf-Klein, G; Zeltser, R, 2015) |
| "We have evaluated the effect of metformin on haemorheology, lipid levels and insulin resistance in insulin-dependent diabetic patients over a 6-week period." | 7.68 | Effects of metformin on haemorheology, lipid parameters and insulin resistance in insulin-dependent diabetic patients (IDDM). ( De Leeuw, I; Janssen, M; Rillaerts, E, 1991) |
| "Metformin treatment was associated with decreases in testosterone, free androgen index, androstenedione, 17-OH progesterone and estradiol levels." | 6.78 | Metformin for the treatment of hyperandrogenism in adolescents with type 1 diabetes mellitus. ( Asenjo, S; Cassorla, F; Codner, E; Eyzaguirre, FC; Iñíguez, G; López, P; Mujica, V; Torrealba, I, 2013) |
| " Primary endpoint was HbA1c, while secondary endpoints were body weight, frequency of hypoglycaemia, blood pressure, lipids, insulin dosage and self-monitored blood glucose profiles were measured." | 6.74 | The effect of metformin in overweight patients with type 1 diabetes and poor metabolic control. ( Beck-Nielsen, H; Henriksen, JE; Jacobsen, IB, 2009) |
| "Metformin showed favourable effect on GV in overweight/obese T1DM patients and reduction in systolic blood pressure, TDD insulin, fasting venous glucose and fructosamine." | 5.69 | Effects of metformin on glycaemic variability in combination with insulin in overweight/obese patients with type 1 diabetes. ( Adam, NLB; Chin Voon, T; Long Bidin, MBB; Poh Shean, W, 2023) |
| "Type 2 diabetes (T2D) and cancer have been shown to be part of the DM1 phenotype." | 5.56 | Diabetes, metformin and cancer risk in myotonic dystrophy type I. ( Alsaggaf, R; Amr, S; Gadalla, SM; Greene, MH; Pfeiffer, RM; St George, DMM; Wagner, KR; Wang, Y; Zhan, M, 2020) |
| "Oral metformin supplementation once daily for 24 weeks as an adjuvant therapy to intensive insulin in pediatric T1DM was safe and effective in improving glycemic control, dyslipidemia and Nrg-4 levels; hence, it decreased inflammation, microvascular complications and subclinical atherosclerosis." | 5.51 | Effect of metformin as an add-on therapy on neuregulin-4 levels and vascular-related complications in adolescents with type 1 diabetes: A randomized controlled trial. ( Elbarbary, NS; Ghallab, MA; Ismail, EAR, 2022) |
| " Whether metformin improves hepatic, muscle or adipose tissue insulin sensitivity has not been studied in adults with Type 1 diabetes." | 5.41 | Insulin resistance in type 1 diabetes managed with metformin (INTIMET): Study protocol of a double-blind placebo-controlled, randomised trial. ( Bruce, C; Evans, J; Greenfield, JR; Holmes-Walker, DJ; Kowalski, G; Liu, Z; Samocha-Bonet, D; Snaith, JR, 2021) |
| "Measure peripheral, hepatic, and adipose insulin sensitivity before and after metformin or placebo therapy in youth with obesity with type 1 diabetes." | 5.30 | Metformin Improves Peripheral Insulin Sensitivity in Youth With Type 1 Diabetes. ( Bergman, BC; Cengiz, E; Cree-Green, M; Fox, LA; Hannon, TS; Kahn, D; Libman, I; Miller, K; Nadeau, KJ; Nathan, B; Pyle, L; Tansey, M; Tichy, E; Tsalikian, E, 2019) |
| "To determine the relationship between the serum fetuin and insulin resistance in Type 1 diabetes subjects and the effect of short-term Metformin therapy on this relationship." | 5.27 | Effect of Metformin Therapy on Serum Fetuin Levels in Insulin Resistant Type 1 Diabetics. ( Abdelsalam, MM; Ahmed, IZ; Eid, YM; Mahdy, MM; Mansour, HK; Sheriba, NA, 2018) |
| "To improve insulin sensitivity, insulin-sensitizing drugs such as metformin are commonly used in overweight and obese T1D patients." | 5.24 | A pilot study of D-chiro-inositol plus folic acid in overweight patients with type 1 diabetes. ( Defeudis, G; Del Toro, R; Fioriti, E; Guglielmi, C; Kyanvash, S; Maggi, D; Manfrini, S; Maurizi, AR; Menduni, M; Pantano, AL; Pozzilli, P, 2017) |
| " Metformin, typically used in type 2 diabetes mellitus (T2DM), is a possible adjunct therapy in T1DM to help improve glycemic control and insulin sensitivity." | 5.20 | Effects of low dose metformin in adolescents with type I diabetes mellitus: a randomized, double-blinded placebo-controlled study. ( Alam, S; Campbell, S; Chow, K; Klingensmith, G; Lindquist, K; McFann, K; Nadeau, KJ; Walravens, P, 2015) |
| " Metformin is an insulin sensitising agent which is known to improve vascular health outcomes in type 2 diabetes (T2D) and other individuals with insulin resistance." | 5.17 | Does metformin improve vascular health in children with type 1 diabetes? Protocol for a one year, double blind, randomised, placebo controlled trial. ( Anderson, J; Coppin, B; Couper, J; D'Arcy, B; Gent, R; Olds, T; Peña, AS; Sullivan, T, 2013) |
| "The present study is the first prospective clinical trial evaluating the effect of combined therapy of metformin and insulin on the pool of oxidized and glycated low‑density lipoproteins (LDL) in young patients with type 1 diabetes and concomitant obesity." | 5.17 | Metformin added to intensive insulin therapy reduces plasma levels of glycated but not oxidized low‑density lipoprotein in young patients with type 1 diabetes and obesity in comparison with insulin alone: a pilot study. ( Burchardt, P; Kaczmarek, J; Marcinkaniec, J; Naskręt, D; Tabaczewski, P; Wierusz-Wysocka, B; Wysocki, H; Zawada, A, 2013) |
| "In a randomized, double-blind, cross-over study, we investigated the effect of metformin on blood glucose control and daily insulin dose in overweight patients with Type 1 diabetes." | 5.12 | The effect of metformin on blood glucose control in overweight patients with Type 1 diabetes. ( Ahmed, AB; Khan, AS; McLoughney, CR, 2006) |
| "Adjuvant metformin can improve QOL, insulin sensitivity and glycaemic control in overweight adults with T1DM." | 5.12 | The addition of metformin in type 1 diabetes improves insulin sensitivity, diabetic control, body composition and patient well-being. ( Bascombe, LA; Holt, RI; Moon, RJ, 2007) |
| "To evaluate whether, in adolescents with type 1 diabetes, the addition of metformin to insulin and standard diabetes management results in 1) higher insulin sensitivity and 2) lower HbA1c, fasting glucose, insulin dosage (units per kilogram per day) and BMI." | 5.10 | Metformin as an adjunct therapy in adolescents with type 1 diabetes and insulin resistance: a randomized controlled trial. ( Cummings, E; Daneman, D; Finegood, D; Hamilton, J; Zdravkovic, V, 2003) |
| " The aim of this was to measure the effect of metformin (850 mg/twice daily) on insulin sensitivity." | 5.05 | Metformin improved insulin resistance in type I, insulin-dependent, diabetic patients. ( Aubertin, J; Brottier, E; Gin, H; Messerchmitt, C, 1985) |
| "We conducted a search on Medline, EMBASE, and the Cochrane Library for relevant studies published before May 2014 based on "metformin" and "diabetes mellitus, type 1." | 4.91 | Efficacy and safety of metformin for patients with type 1 diabetes mellitus: a meta-analysis. ( Li, L; Li, P; Liu, C; Wu, D; Zheng, X, 2015) |
| " We conclude that metformin may prove useful in macrovascular disease reduction, while pramlintide, glucagon-like peptide-1 agonists, dipeptidyl peptidase-4 inhibitors and leptin co-therapies may reduce HbA(1c) , glucose variability, postprandial glucose excursions and body weight." | 4.89 | Potential role of non-insulin adjunct therapy in Type 1 diabetes. ( George, P; McCrimmon, RJ, 2013) |
| " Agents that decrease intestinal carbohydrate digestion (alpha-glucosidase inhibitors) or decrease insulin resistance (metformin) might be alternative adjunctive therapies in T1DM, though its benefits are marginally supported by clinical data." | 4.86 | Adjunct therapy for type 1 diabetes mellitus. ( Lebovitz, HE, 2010) |
| "Metformin is widely used for treating patients with type 2 diabetes mellitus." | 4.86 | [New clinical data with metformin therapy in patients with diabetes mellitus]. ( Jermendy, G, 2010) |
| " The present study aimed to determine whether metformin exerts beneficial effects on metabolic and neurobehavioral outcomes in the streptozotocin (STZ)-induced T1D model and western diet (WD)-induced obesity model in male Swiss mice." | 4.31 | Metformin improves neurobehavioral impairments of streptozotocin-treated and western diet-fed mice: Beyond glucose-lowering effects. ( Barbosa, LADS; Barros, WM; Braga, SP; Bullich, S; Delanogare, E; Dos Santos, GJ; Guiard, BP; Kasprowicz, JN; Kraus, SI; Moreira, ELG, 2023) |
| " The diagnosis leaned toward latent autoimmune diabetes in adults, and the therapeutic approach involved cessation of preprandial insulin therapy, regulation, and subsequent discontinuation of basal insulin and introduction of metformin." | 4.12 | Diabetic ketoacidosis as first presentation of latent autoimmune diabetes in adults in a patient with hashitoxicosis as first presentation of Hashimoto's thyroiditis: a case report. ( Fousteris, E; Lygnos, D; Xenou, M; Zoupas, I, 2022) |
| "Treatment with the polyherbal mixture extract was more effective than the standard drugs (insulin and metformin) in the amelioration of hyperglycemia, hyperlipidemia, and histopathological changes of the pancreas, kidney and liver tissue." | 4.02 | Polyherbal mixture ameliorates hyperglycemia, hyperlipidemia and histopathological changes of pancreas, kidney and liver in a rat model of type 1 diabetes. ( Djordjević, L; Jugović, D; Jušković, M; Madić, V; Petrović, A; Stojanović, G; Vasiljević, P, 2021) |
| "To examine (1) effects of short-term metformin treatment on serum holotranscobalamin (holoTC) and folate and (2) their association with insulin sensitivity in recent-onset type 2 diabetes." | 3.96 | Vitamin B12 and Folate Concentrations in Recent-onset Type 2 Diabetes and the Effect of Metformin Treatment. ( Anadol-Schmitz, E; Bobrov, P; Burkart, V; Kahl, S; Kanti, G; Karusheva, Y; Markgraf, DF; Roden, M; Sarabhai, T; Strassburger, K; Szendroedi, J; Trenkamp, S; Zaharia, OP; Ziegler, D, 2020) |
| " This study was set out to explore the molecular mechanism of metformin in the treatment of T1D insulin resistance." | 3.96 | Metformin Decreases Insulin Resistance in Type 1 Diabetes Through Regulating p53 and RAP2A in vitro and in vivo. ( Jiao, PF; Ma, XJ; Ren, GF; Xiao, LL; Yan, YS, 2020) |
| "Metformin decreased glucose concentrations, reduced metabolic syndrome, as well as insulin dose requirement more than insulin therapy alone, 1 year after treatment." | 3.88 | The effects of metformin in type 1 diabetes mellitus. ( Beysel, S; Cakal, E; Caliskan, M; Kizilgul, M; Ucan, B; Unsal, IO, 2018) |
| " A 16-year-old young-boy, diagnosed with autism, developed diabetes mellitus type 1 whilst he was on treatment with olanzapine (started 4 months before), clomipramine, valproic acid and lithium." | 3.85 | Second-generation antipsychotic and diabetes mellitus in children and adolescents. ( Nurchi, AM; Pinna, AP; Podda, F; Ripoli, C; Tronci, MG; Zanni, R, 2017) |
| "Polycystic ovary syndrome (PCOS) is common in obese women with insulin resistant type 2 diabetes for which metformin treatment is getting established in addition to clomiphene." | 3.83 | A case of lean polycystic ovary syndrome with early stage of type 1 diabetes successfully treated with metformin. ( Hirose, T; Kitamura, M; Kumashiro, N; Rikitake, T; Saegusa, M; Shigiyama, F; Uchino, H; Usui, S, 2016) |
| "The skin matrix metalloproteinase 3, tissue inhibitors of matrix metalloproteinase 2 and collagen III content changes in type 1 diabetes and insulin resistance treated with insulin and metformin were studied." | 3.81 | The skin remodeling in type 1 diabetes and insulin resistance animal models. ( Kasacka, I; Knaś, M; Mikucka-Niczyporuk, A; Niczyporuk, M; Wołosik, K; Zalewska, A, 2015) |
| "No statistically significant association of cardioprotection was found between metformin and myocardial infarct size in patients with diabetes and acute ST-segment elevation myocardial infarction." | 3.81 | Metformin and Myocardial Injury in Patients With Diabetes and ST-Segment Elevation Myocardial Infarction: A Propensity Score Matched Analysis. ( Akerman, M; Basnet, S; Kozikowski, A; Lesser, M; Makaryus, AN; Pekmezaris, R; Wolf-Klein, G; Zeltser, R, 2015) |
| "Right atrial sections from four patient groups-non-diabetic, insulin-dependent diabetes mellitus (IDDM), non-insulin-dependent diabetes mellitus (NIDDM) receiving glibenclamide, and NIDDM receiving metformin-were subjected to one of the following protocols: aerobic control, simulated ischemia/reoxygenation, ischemic preconditioning before ischemia, and pharmacological preconditioning with alpha 1 agonist phenylephrine, adenosine, the mito-K(ATP) channel opener diazoxide, the protein kinase C (PKC) activator phorbol-12-myristate-13-acetate (PMA), or the p38 mitogen-activated protein kinase (p38MAPK) activator anisomycin." | 3.73 | Mitochondrial dysfunction as the cause of the failure to precondition the diabetic human myocardium. ( Fowler, A; Galiñanes, M; Hassouna, A; Loubani, M; Matata, BM; Standen, NB, 2006) |
| "After adding metformin to the insulin regimen of type 2 diabetics after three months a statistically significant drop of body weight and the daily insulin dose occurred." | 3.71 | [Short-term and long-term effect of metformin in type 1 diabetics]. ( Cechurová, D; Jankovec, Z; Kárová, R; Kyselová, P; Lacigová, S; Rusavý, Z, 2001) |
| "We have evaluated the effect of metformin on haemorheology, lipid levels and insulin resistance in insulin-dependent diabetic patients over a 6-week period." | 3.68 | Effects of metformin on haemorheology, lipid parameters and insulin resistance in insulin-dependent diabetic patients (IDDM). ( De Leeuw, I; Janssen, M; Rillaerts, E, 1991) |
| "It included 80 patients of Type 1 Diabetes above 12 years of age between April 2019 to March 2020." | 3.30 | Effect of Metformin as adjunct therapy with insulin in adolescent Pakistani people with type 1 diabetes. ( Amina Raza, -; Asher Fawwad, -; Fasiha Fatima, -; Iftikhar Ahmed, -; Madiha Soban, -; Ruqaya Nangrejo, -, 2023) |
| " We aimed to examine the effect of metformin on glycemic indices and insulin daily dosage in adolescents with T1DM." | 3.11 | Benefits of metformin add-on insulin therapy (MAIT) for HbA1c and lipid profile in adolescents with type 1 diabetes mellitus: preliminary report from a double-blinded, placebo-controlled, randomized clinical trial. ( Alaei, M; Eydian, Z; Fallahzadeh, A; Hajipour, M; Mosallanejad, A; Saneifard, H; Shakiba, M; Sheikhy, A, 2022) |
| "40 individuals with type 1 diabetes (average age of 44." | 3.11 | Empagliflozin-Metformin Combination Has Antioxidative and Anti-Inflammatory Properties that Correlate with Vascular Protection in Adults with Type 1 Diabetes. ( Cankar, M; France Štiglic, A; Janež, A; Janić, M; Jerin, A; Lunder, M; Šabovič, M; Šmid, J, 2022) |
| "Cognizant of the burden of type 1 diabetes, the recommendations also highlight the importance of research to advance our understanding of the etiology of and opportunities for prevention of type 1 diabetes." | 3.01 | The National Clinical Care Commission Report to Congress: Leveraging Federal Policies and Programs to Prevent Diabetes in People With Prediabetes. ( Boltri, JM; Fukagawa, N; Herman, WH; Idzik, S; Leake, E; Powell, C; Schumacher, P; Shell, D; Strogatz, D; Tracer, H; Wu, S, 2023) |
| "Youth with type 1 diabetes (T1D) have normal or elevated High-Density Lipoprotein Cholesterol (HDL-C), however, the function of HDL, partly mediated by the HDL proteome, may be impaired." | 3.01 | Effect of metformin on the high-density lipoprotein proteome in youth with type 1 diabetes. ( Gordon, SM; Gourgari, E; Ma, J; Mehta, NN; Nadeau, KJ; Playford, MP; Pyle, L; Remaley, AT, 2021) |
| "Youth with type 1 diabetes (T1D) carry greater cardiovascular disease (CVD) risk than their nondiabetic peers." | 2.90 | Serum uromodulin inversely associates with aortic stiffness in youth with type 1 diabetes: A brief report from EMERALD study. ( Baumgartner, A; Bjornstad, P; Coe, G; Cree-Green, M; Johnson, RJ; Nadeau, KJ; Pyle, L; Reyes, YG; Roncal, C; Schäfer, M; Truong, U; Wiromrat, P, 2019) |
| "Metformin was administered for at least 6 months in 74 patients, while 40 patients did not receive metformin." | 2.87 | Metformin added to intensive insulin therapy improves metabolic control in patients with type 1 diabetes and excess body fat. ( Burchardt, P; Grzymisławski, M; Naskręt, D; Niedźwiecki, P; Piłaciński, S; Wierusz-Wysocka, B; Zawada, A; Zozulińska-Ziółkiewicz, D, 2018) |
| "Adolescents with type 1 diabetes have early macrovascular changes (increased intima-media thickness [IMT]) and early retinal changes that predict clinical disease in adulthood." | 2.87 | Early atherosclerosis is associated with retinal microvascular changes in adolescents with type 1 diabetes. ( Anderson, J; Couper, JJ; Gent, R; Giles, LC; Liew, G; Peña, AS; Wong, TY, 2018) |
| "Children with type 1 diabetes have vascular dysfunction preceding atherosclerosis." | 2.84 | Effect of Metformin on Vascular Function in Children With Type 1 Diabetes: A 12-Month Randomized Controlled Trial. ( Anderson, JJA; Coppin, B; Couper, JJ; Gent, R; Giles, LC; Leggett, CE; Peña, AS, 2017) |
| " The primary outcome was the HbA1c level, and secondary outcomes included the body mass index (BMI), total insulin daily dose (TIDD) (unit/kg/d), hypoglycemia events, diabetes ketoacidosis (DKA) events, and gastrointestinal adverse events (GIAEs)." | 2.82 | Effect and Safety of Adding Metformin to Insulin Therapy in Treating Adolescents With Type 1 Diabetes Mellitus: An Updated Meta-Analysis of 10 Randomized Controlled Trials. ( Chen, H; Li, H; Li, L; Liu, Y; Wu, J, 2022) |
| "Metformin has potential cardio-protective effect through improving cEPCs, CFU-Hill's colonies, cECs, PACs count and function independently of hypoglycaemic effect." | 2.82 | Metformin improves circulating endothelial cells and endothelial progenitor cells in type 1 diabetes: MERIT study. ( Ahmed, FW; Glanville, M; Narayanan, K; Razvi, S; Rider, R; Weaver, JU, 2016) |
| "Among overweight adolescents with type 1 diabetes, the addition of metformin to insulin did not improve glycemic control after 6 months." | 2.80 | Effect of Metformin Added to Insulin on Glycemic Control Among Overweight/Obese Adolescents With Type 1 Diabetes: A Randomized Clinical Trial. ( Beck, RW; Bethin, KE; Coffey, JK; DiMeglio, LA; Haller, MJ; Katz, ML; Libman, IM; Miller, KM; Nadeau, KJ; Raman, S; Saenz, AM; Shah, A; Simmons, JH; Tamborlane, WV, 2015) |
| "We recruited 25 patients with type 1 diabetes (mean age 51 ± 10 years, mean disease duration 26 ± 13 years) and 31 insulin-treated type 2 diabetic patients (mean age 66 ± 8 years, mean disease duration 19 ± 9 years), who received sitagliptin with metformin as a fixed-dose combination (50/1000 mg once or twice daily) or sitagliptin (100 mg once daily, if intolerant to metformin) in addition to ongoing insulin therapy for 46 ± 19 weeks and 56 ± 14 weeks, respectively." | 2.78 | Sitagliptin as add-on therapy in insulin deficiency: biomarkers of therapeutic efficacy respond differently in type 1 and type 2 diabetes. ( Bartola, LD; Giampietro, C; Giampietro, O; Masoni, MC; Matteucci, E, 2013) |
| "Metformin treatment was associated with decreases in testosterone, free androgen index, androstenedione, 17-OH progesterone and estradiol levels." | 2.78 | Metformin for the treatment of hyperandrogenism in adolescents with type 1 diabetes mellitus. ( Asenjo, S; Cassorla, F; Codner, E; Eyzaguirre, FC; Iñíguez, G; López, P; Mujica, V; Torrealba, I, 2013) |
| "However, the rate of progression to SPIDDM with the use of insulin-sensitizing agents is unknown." | 2.76 | Pioglitazone may accelerate disease course of slowly progressive type 1 diabetes. ( Katsuki, T; Oikawa, Y; Okubo, Y; Shigihara, T; Shimada, A; Yamada, Y, 2011) |
| " Primary endpoint was HbA1c, while secondary endpoints were body weight, frequency of hypoglycaemia, blood pressure, lipids, insulin dosage and self-monitored blood glucose profiles were measured." | 2.74 | The effect of metformin in overweight patients with type 1 diabetes and poor metabolic control. ( Beck-Nielsen, H; Henriksen, JE; Jacobsen, IB, 2009) |
| "In contrast, in patients with type 1 diabetes (T1DM), information about the effect of metformin treatment on lipidaemia is limited." | 2.74 | Effect of adjunct metformin treatment on levels of plasma lipids in patients with type 1 diabetes. ( Alibegovic, AC; Astrup, AS; Frandsen, M; Hovind, P; Jacobsen, PK; Lund, SS; Parving, HH; Parving, I; Pietraszek, L; Rossing, P; Tarnow, L; Vaag, AA, 2009) |
| "Metformin is an oral hypoglycaemic agent that improves insulin action in patients with type-2 diabetes." | 2.73 | Effect of adjunct metformin treatment in patients with type-1 diabetes and persistent inadequate glycaemic control. A randomized study. ( Alibegovic, AC; Astrup, AS; Frandsen, M; Hovind, P; Jacobsen, PK; Lund, SS; Parving, HH; Parving, I; Pietraszek, L; Rossing, P; Tarnow, L; Vaag, AA, 2008) |
| "Troglitazone treatment of type 2 diabetic patients diminishes sCD40L levels, suggesting a novel antiinflammatory mechanism for limiting diabetes-associated arterial disease." | 2.71 | Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones. ( Bernal, MR; Calle-Pascual, AL; Fernández-Cruz, A; Goldfine, A; Horton, E; Jarolim, P; Libby, P; Nuzzo, R; Schönbeck, U; Varo, JJ; Varo, N; Veves, A; Vicent, D, 2003) |
| "1% and daily insulin dosage 1." | 2.71 | Metformin as additional therapy in adolescents with poorly controlled type 1 diabetes: randomised placebo-controlled trial with aspects on insulin sensitivity. ( Aman, J; Kroon, M; Särnblad, S, 2003) |
| "Treatment with metformin was associated with a reduction in daily insulin requirements between V0 and V6 of -4." | 2.70 | The benefits of metformin therapy during continuous subcutaneous insulin infusion treatment of type 1 diabetic patients. ( Bohme, P; Cugnardey, N; Delbachian, I; Drouin, P; Guerci, B; Lehert, P; Meyer, L, 2002) |
| "Metformin is an oral hypoglycemic agent extensively used as first-line therapy for type 2 diabetes." | 2.66 | Metformin: Up to Date. ( De Pergola, G; Giagulli, VA; Grimaldi, F; Guastamacchia, E; Iacoviello, M; Licchelli, B; Sciannimanico, S; Triggiani, V; Vescini, F, 2020) |
| "Individuals with type 1 diabetes (T1D) frequently fail to achieve glycemic goals and have excess cardiovascular risk and premature death." | 2.66 | Reducing Type 1 Diabetes Mortality: Role for Adjunctive Therapies? ( Greenfield, JR; Holmes-Walker, DJ; Snaith, JR, 2020) |
| "Metformin treatment significantly reduced carotid artery intima-media thickness (MD -0." | 2.66 | Vascular and metabolic effects of metformin added to insulin therapy in patients with type 1 diabetes: A systematic review and meta-analysis. ( Chen, CN; Chen, ZG; Lin, XP; Liu, YS; Peng, Y; Xu, LL, 2020) |
| "Metformin was associated with reductions in BMI (-1." | 2.58 | Effect of metformin on glycaemic control in patients with type 1 diabetes: A meta-analysis of randomized controlled trials. ( Hao, J; Liang, Y; Lu, J; Meng, H; Zhang, A; Zhang, X, 2018) |
| "Therapy for type 1 diabetes (T1D) is mainly restricted to insulin treatment." | 2.58 | Novel blood glucose lowering therapies for managing type 1 diabetes in paediatric patients. ( Naciu, AM; Pozzilli, P, 2018) |
| "Metformin is a widely prescribed medication that has been used to treat children with type 2 diabetes in the United States for the past 15 years." | 2.55 | Metformin; a review of its history and future: from lilac to longevity. ( Gregg, B; Thomas, I, 2017) |
| "Insulin treatment of individuals with type 1 diabetes has shortcomings and many patients do not achieve glycaemic and metabolic targets." | 2.53 | Non-insulin drugs to treat hyperglycaemia in type 1 diabetes mellitus. ( Dejgaard, TF; Frandsen, CS; Madsbad, S, 2016) |
| "Iatrogenic and compensatory hyperinsulinemia are metabolic disruptors of β-cells, liver, muscle, kidney, brain, heart and vasculature, inflammation, and lipid homeostasis, among other systems." | 2.53 | Obviating much of the need for insulin therapy in type 2 diabetes mellitus: A re-assessment of insulin therapy's safety profile. ( Herman, ME; Jellinger, PS; Schwartz, SS, 2016) |
| "Long-standing type 1 diabetes and type 2 diabetes increase the risk for this malignancy, but the cancer can also induce pancreatogenic, or type 3c, diabetes as well." | 2.49 | Diabetes and cancer: placing the association in perspective. ( Andersen, DK, 2013) |
| "Management of type 1 diabetes essentially relies upon intensive insulin therapy adjusted according to careful home blood glucose monitoring." | 2.49 | [Limited add-on value of oral glucose-lowering agents in type 1 diabetes]. ( Scheen, AJ, 2013) |
| "Adolescents with type 1 diabetes mellitus (DM1) often have problems in achieving optimal glycaemic control." | 2.47 | [Metformin in adolescents and adults with type 1 diabetes mellitus: not evidence-based]. ( Aanstoot, HJ; Bilo, HJ; Brand, PL; Kleefstra, N; Spaans, EA; van Hateren, KJ, 2011) |
| "Type 2 diabetes is associated with increased risk of breast, colon, pancreatic and other types of cancer, while type 1 diabetes is associated with increase in stomach, pancreatic, endometrial and cervical cancer." | 2.47 | Diabetes mellitus and the risk of cancer. ( Abdallah, M; Alickaj, A; Asad, S; Forte, V; Mahmud, S; McFarlane, SI; Pandey, A, 2011) |
| "Metformin was associated with reductions in: (1) insulin-dose requirement (5." | 2.46 | The use of metformin in type 1 diabetes: a systematic review of efficacy. ( Buetow, L; Colhoun, HM; Livingstone, S; Petrie, JR; Royle, P; Vella, S, 2010) |
| " Improvements in insulin sensitivity, body composition or serum lipids were not documented in either study, however, one study showed a decrease in insulin dosage by 10%." | 2.45 | Metformin added to insulin therapy for type 1 diabetes mellitus in adolescents. ( Abdelghaffar, S; Attia, AM, 2009) |
| "In many patients with type 2 diabetes, hyperglycemia can be reduced with appropriate changes in diet and exercise, however, some patients with type 2 diabetes and insulin resistance syndromes need pharmacological therapy to improve their metabolic control." | 2.45 | [Could oral antidiabetic agents be useful in the management of different types of diabetes and syndromes of insulin resistance in children and adolescents?]. ( Jarosz-Chobot, P; Nowowiejska, B; Otto-Buczkowska, E; Stańczyk, J, 2009) |
| "Insulin resistance is an independent risk factor for the development of macro- and microvascular complications of Type 1 diabetes and may also contribute to the development of the disease." | 2.44 | Addressing insulin resistance in Type 1 diabetes. ( Narendran, P; Pang, TT, 2008) |
| "However, hyperglycemia (especially postprandial hyperglycemia) and hypoglicemia continue to be problematic in the management of type 1 diabetes." | 2.44 | [Adjunctive therapies to glycaemic control of type 1 diabetes mellitus]. ( Gabbay, Mde A, 2008) |
| "Metformin is a first-line drug in the treatment of overweight and obese type 2 diabetic patients, offering a selective pathophysiological approach by its effect on insulin resistance." | 2.42 | Current indications for metformin therapy. ( Tankova, T, 2003) |
| "Metformin treatment improved fasting hyperglycemia in these patients through a reduction in hepatic glucose production, which could be attributed to a decrease in gluconeogenesis." | 2.41 | Nuclear magnetic resonance studies of hepatic glucose metabolism in humans. ( Petersen, KF; Roden, M; Shulman, GI, 2001) |
| "Treatment with rutin and metformin in combination significantly reduced PE-induced contraction and increased ACh-induced and SNP-induced relaxation in diabetes when compared to rutin or metformin alone." | 1.91 | Influence of rutin and its combination with metformin on vascular functions in type 1 diabetes. ( Chakravarthi, S; Chellian, J; David, SR; Lai, PPN; Rajabalaya, R, 2023) |
| "Metformin was administered to T1DM subjects for eight weeks." | 1.91 | Decoding of miR-7-5p in Colony Forming Unit-Hill Colonies as a Biomarker of Subclinical Cardiovascular Disease-A MERIT Study. ( Bakhashab, S; Mahaputra, DK; Megantara, HP; O'Neill, J; Phowira, J; Weaver, JU, 2023) |
| "Maturity-onset Diabetes of Young (MODY) is a monogenic form of diabetes affecting 1-5% of young (often ≤25 years) diabetic patients exhibiting an autosomal dominant mode of inheritance." | 1.72 | Clinical profiling and screening for HNF4α and GCK gene mutations in Kashmiri patients with maturity-onset diabetes of the young (MODY). ( Firdous, P; Ganai, BA; Hassan, T; Masoodi, SR; Nissar, K, 2022) |
| "Metformin, a drug widely used in type 2 diabetes (T2D), has been shown to protect human β-cells exposed to gluco- and/or lipotoxic conditions and those in islets from T2D donors." | 1.72 | The Protective Action of Metformin against Pro-Inflammatory Cytokine-Induced Human Islet Cell Damage and the Mechanisms Involved. ( Ciregia, F; Cnop, M; De Luca, C; Del Guerra, S; Eizirik, DL; Giusti, L; Lucacchini, A; Marchetti, P; Marselli, L; Mazzoni, MR; Ronci, M; Suleiman, M; Tesi, M; Trerotola, M; Zallocco, L; Zuccarini, M, 2022) |
| "Metformin is a biguanide that exhibits antidiabetic, anticarcinogenic, and anti-inflammatory properties." | 1.72 | High Throughput Study for Molecular Mechanism of Metformin Pre-Diabetic Protection via Microarray Approach. ( Al Shhab, MA; Alrawashdeh, AY; Zihlif, MA, 2022) |
| "Metformin was the most frequently drug initially prescribed in noninsulin treated subjects (~85%) and sulphonylurea receptor (SUR) agonists collectively ranked as second (~13%)." | 1.62 | Initial treatment of diabetes in Italy. A nationwide population-based study from of the ARNO Diabetes Observatory. ( Bonora, E; Cataudella, S; Fadini, GP; Marchesini, G; Martini, N; Miccoli, R; Rossi, E; Vaccaro, O, 2021) |
| "Treatment with metformin improved these parameters." | 1.62 | Metformin mitigates impaired testicular lactate transport/utilisation and improves sexual behaviour in streptozotocin-induced diabetic rats. ( Abu Bakar, AB; Ahmad, A; Mohamed, M; Nna, VU, 2021) |
| "Type 2 diabetes (T2D) and cancer have been shown to be part of the DM1 phenotype." | 1.56 | Diabetes, metformin and cancer risk in myotonic dystrophy type I. ( Alsaggaf, R; Amr, S; Gadalla, SM; Greene, MH; Pfeiffer, RM; St George, DMM; Wagner, KR; Wang, Y; Zhan, M, 2020) |
| "Metformin functions as a stabilizer of atherosclerotic plaque to reduce acute coronary accent." | 1.48 | AMPKα inactivation destabilizes atherosclerotic plaque in streptozotocin-induced diabetic mice through AP-2α/miRNA-124 axis. ( Chen, Y; Guo, T; Liang, WJ; Shan, MR; Wang, SX; Wang, XQ; Zhang, M; Zhang, Y; Zhou, SN, 2018) |
| "Type 1 diabetes care requires i) insulin treatment, food intake and life style to be handled in concert, ii) this need cannot be replaced by arbitrary addition of add-on GLDs, and iii) training to this end is 75% cheaper at a DRC than in standard hospitals." | 1.48 | Type 1 diabetes care: Improvement by standardization in a diabetes rehabilitation clinic. An observational report. ( Fallmann, H; Hartmann, E; Haslacher, H; Wagner, OF; Waldhäusl, C; Waldhäusl, W, 2018) |
| "Give a sulfonylurea to patients with type 2 diabetes who do not achieve glycemic control with metformin alone or who have contraindications to metformin (strong recommendation, moderate-quality evidence)." | 1.48 | Medicines for Treatment Intensification in Type 2 Diabetes and Type of Insulin in Type 1 and Type 2 Diabetes in Low-Resource Settings: Synopsis of the World Health Organization Guidelines on Second- and Third-Line Medicines and Type of Insulin for the Con ( Norris, SL; Roglic, G, 2018) |
| "Only metformin monotherapy was not associated with an increased 5-year mortality compared with matched controls, whereas individuals on a combination of sulfonylurea and insulin had the highest mortality risks." | 1.43 | Mortality in Individuals Treated With Glucose-Lowering Agents: A Large, Controlled Cohort Study. ( Callens, M; Claesen, M; De Moor, B; De Smet, F; Gillard, P; Mathieu, C, 2016) |
| "Metformin was the most frequently prescribed medication (77." | 1.43 | The prevalence and treatment patterns of diabetes in the Greek population based on real-world data from the nation-wide prescription database. ( Dafoulas, GE; Kani, C; Liatis, S; Litsa, P; Makrilakis, K; Politi, A; Sfikakis, PP, 2016) |
| "Metformin has been considered a potential adjunctive therapy in treating poorly controlled type 1 diabetes with obesity and insulin resistance, owing to its potent effects on improving insulin sensitivity." | 1.42 | New Insight Into Metformin Action: Regulation of ChREBP and FOXO1 Activities in Endothelial Cells. ( Clements, MA; Heruth, DP; Jackson, K; Kover, KL; Li, X; Moore, WV; Watkins, DJ; Yan, Y; Zang, M, 2015) |
| "Characteristic findings of type 1 and type 2 diabetes may be present simultaneously." | 1.40 | [Difficult diagnosis in a 17-year-old patient: Type 1 diabetes? Type 2 diabetes? Or "double diabetes"?]. ( Engelsberger, I; Warncke, K, 2014) |
| "Presently, type 2 diabetes (T2D) can neither be prevented nor cured and the disease is associated with devastating chronic complications." | 1.40 | Can genetics improve precision of therapy in diabetes? ( Groop, L; Rosengren, A; Storm, P, 2014) |
| "Cryptococcosis is an opportunistic infection caused by Cryptococcus neoformans that typically presents in immunocompromised patients, most commonly in those with human immunodeficiency virus (HIV) infection." | 1.40 | Disseminated cryptococcosis in a diabetic patient. ( Khatu, S; Poojary, S, 2014) |
| "At SPIDDM diagnosis, he was in a non-insulin-dependent state, with a fasting serum C-peptide immunoreactivity level of 2." | 1.39 | Slowly progressive type 1 diabetes treated with metformin for five years after onset. ( Hirata, T; Maruyama, T; Morimoto, J; Shimada, A, 2013) |
| "Metformin treatment did not affect body weight, fasting blood glucose and arterial blood pressure." | 1.39 | Effects of two weeks of metformin treatment on whole-body glycocalyx barrier properties in db/db mice. ( Eskens, BJ; van Haare, J; van Teeffelen, JW; Vink, H; Zuurbier, CJ, 2013) |
| "Metformin-treated patients, especially elderly ones, are at a risk of sudden deterioration of renal function, which in turn may increase the risk of lactic acidosis." | 1.39 | Lactic acidosis in patients with diabetes. ( Karnafel, W; Krzymień, J, 2013) |
| "Renal hypertrophy in rats with Type 1 diabetes was associated with reduction in AMPK phosphorylation and increased mTOR activity." | 1.34 | A role for AMP-activated protein kinase in diabetes-induced renal hypertrophy. ( Choudhury, GG; Feliers, D; Foretz, M; Kasinath, BS; Lee, MJ; Mahimainathan, L; Mariappan, MM; Musi, N; Sataranatarajan, K; Viollet, B; Weinberg, JM, 2007) |
| "Type 2 diabetes mellitus is a chronic disease with potentially devastating long-term complications." | 1.33 | Oral agents in managing diabetes mellitus in children and adolescents. ( Jacobson-Dickman, E; Levitsky, L, 2005) |
| "Significantly more participants with type 2 diabetes using oral drugs than those with type 1 diabetes and using insulin preferred inhaled insulin (98." | 1.33 | Willingness to pay for inhaled insulin: a contingent valuation approach. ( Einarson, TR; Leiter, LA; MacKeigan, LD; Sadri, H, 2005) |
| "For individuals (n = 4,005) with type 1 diabetes, 79% had a DP record for supplies, with an average annual cost of 472 +/- 560 dollars." | 1.33 | Utilization of diabetes medication and cost of testing supplies in Saskatchewan, 2001. ( Hirji, Z; Johnson, JA; Pohar, SL; Secnik, K; Yurgin, N, 2006) |
| "Chronic diarrhea is more frequent in type I diabetic patients." | 1.30 | The prevalence of chronic diarrhea among diabetic patients. ( Goldin, E; Israeli, E; Lysy, J, 1999) |
| " The IGF-I dose-response curve was similar for CMCs of control and IDDM individuals, but both the basal and maximal response to IGF-I were lower in the diabetic group (P < ." | 1.29 | Regulation of glucose transport and expression of GLUT3 transporters in human circulating mononuclear cells: studies in cells from insulin-dependent diabetic and nondiabetic individuals. ( Daneman, D; Elliott, E; Estrada, DE; Klip, A; Liu, Z; Poon, I; Zinman, B, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (4.76) | 18.7374 |
| 1990's | 16 (6.93) | 18.2507 |
| 2000's | 43 (18.61) | 29.6817 |
| 2010's | 115 (49.78) | 24.3611 |
| 2020's | 46 (19.91) | 2.80 |
| Authors | Studies |
|---|---|
| Firdous, P | 1 |
| Hassan, T | 1 |
| Nissar, K | 1 |
| Masoodi, SR | 1 |
| Ganai, BA | 1 |
| Sheikhy, A | 1 |
| Eydian, Z | 1 |
| Fallahzadeh, A | 1 |
| Shakiba, M | 1 |
| Hajipour, M | 1 |
| Alaei, M | 1 |
| Mosallanejad, A | 1 |
| Saneifard, H | 1 |
| Elbarbary, NS | 1 |
| Ismail, EAR | 1 |
| Ghallab, MA | 1 |
| Janić, M | 2 |
| Cankar, M | 1 |
| Šmid, J | 1 |
| France Štiglic, A | 1 |
| Jerin, A | 1 |
| Šabovič, M | 2 |
| Janež, A | 2 |
| Lunder, M | 2 |
| Liu, Y | 1 |
| Chen, H | 1 |
| Li, H | 2 |
| Li, L | 2 |
| Wu, J | 1 |
| Xenou, M | 1 |
| Zoupas, I | 1 |
| Lygnos, D | 1 |
| Fousteris, E | 1 |
| Giusti, L | 2 |
| Tesi, M | 1 |
| Ciregia, F | 1 |
| Marselli, L | 1 |
| Zallocco, L | 1 |
| Suleiman, M | 1 |
| De Luca, C | 1 |
| Del Guerra, S | 1 |
| Zuccarini, M | 1 |
| Trerotola, M | 1 |
| Eizirik, DL | 1 |
| Cnop, M | 1 |
| Mazzoni, MR | 1 |
| Marchetti, P | 1 |
| Lucacchini, A | 1 |
| Ronci, M | 1 |
| Delanogare, E | 1 |
| Bullich, S | 1 |
| Barbosa, LADS | 1 |
| Barros, WM | 1 |
| Braga, SP | 1 |
| Kraus, SI | 1 |
| Kasprowicz, JN | 1 |
| Dos Santos, GJ | 1 |
| Guiard, BP | 1 |
| Moreira, ELG | 1 |
| Shestakova, MV | 1 |
| Vikulova, OK | 1 |
| Elfimova, AR | 1 |
| Deviatkin, AA | 1 |
| Dedov, II | 1 |
| Mokrysheva, NG | 1 |
| Zhang, J | 3 |
| Deng, Y | 3 |
| Wan, Y | 3 |
| Wang, J | 4 |
| Xu, J | 3 |
| Pereira, ADS | 1 |
| Miron, VV | 1 |
| Castro, MFV | 1 |
| Bottari, NB | 1 |
| Assmann, CE | 1 |
| Nauderer, JN | 1 |
| Bissacotti, BF | 1 |
| Mostardeiro, VB | 1 |
| Stefanello, N | 1 |
| Baldissarelli, J | 2 |
| Palma, TV | 1 |
| Morsch, VMM | 1 |
| Schetinger, MRC | 1 |
| Dias, HF | 1 |
| Mochizuki, Y | 1 |
| Kühtreiber, WM | 1 |
| Takahashi, H | 1 |
| Zheng, H | 1 |
| Faustman, DL | 1 |
| Boltri, JM | 1 |
| Tracer, H | 1 |
| Strogatz, D | 1 |
| Idzik, S | 1 |
| Schumacher, P | 1 |
| Fukagawa, N | 1 |
| Leake, E | 1 |
| Powell, C | 1 |
| Shell, D | 1 |
| Wu, S | 1 |
| Herman, WH | 2 |
| Yan, X | 1 |
| Li, X | 3 |
| Liu, B | 1 |
| Huang, J | 1 |
| Xiang, Y | 1 |
| Hu, Y | 1 |
| Tang, X | 1 |
| Zhang, Z | 1 |
| Huang, G | 1 |
| Xie, Z | 1 |
| Zhou, H | 1 |
| Liu, Z | 3 |
| Wang, X | 1 |
| Leslie, RD | 1 |
| Zhou, Z | 1 |
| Poh Shean, W | 1 |
| Chin Voon, T | 1 |
| Long Bidin, MBB | 1 |
| Adam, NLB | 1 |
| Ismail, HM | 1 |
| Barua, S | 1 |
| Sabharwal, A | 1 |
| Libman, I | 2 |
| Bacha, F | 2 |
| Nadeau, KJ | 6 |
| Tosur, M | 1 |
| Redondo, MJ | 1 |
| David, SR | 1 |
| Lai, PPN | 1 |
| Chellian, J | 1 |
| Chakravarthi, S | 1 |
| Rajabalaya, R | 1 |
| Bakhashab, S | 2 |
| Megantara, HP | 1 |
| Mahaputra, DK | 1 |
| O'Neill, J | 1 |
| Phowira, J | 1 |
| Weaver, JU | 3 |
| Amina Raza, - | 1 |
| Iftikhar Ahmed, - | 1 |
| Asher Fawwad, - | 1 |
| Fasiha Fatima, - | 1 |
| Ruqaya Nangrejo, - | 1 |
| Madiha Soban, - | 1 |
| Langford, BE | 1 |
| Evans, M | 1 |
| Haskins-Coulter, T | 1 |
| O'Connor, M | 1 |
| Cant, HEO | 1 |
| Eddowes, LA | 1 |
| Edmonds, C | 1 |
| Tank, A | 1 |
| Sciannimanico, S | 1 |
| Grimaldi, F | 1 |
| Vescini, F | 1 |
| De Pergola, G | 1 |
| Iacoviello, M | 1 |
| Licchelli, B | 1 |
| Guastamacchia, E | 1 |
| Giagulli, VA | 1 |
| Triggiani, V | 1 |
| Alsaggaf, R | 1 |
| Pfeiffer, RM | 1 |
| Wang, Y | 1 |
| St George, DMM | 1 |
| Zhan, M | 1 |
| Wagner, KR | 1 |
| Amr, S | 1 |
| Greene, MH | 1 |
| Gadalla, SM | 1 |
| Snaith, JR | 2 |
| Holmes-Walker, DJ | 2 |
| Greenfield, JR | 2 |
| Kanti, G | 1 |
| Anadol-Schmitz, E | 1 |
| Bobrov, P | 1 |
| Strassburger, K | 1 |
| Kahl, S | 1 |
| Zaharia, OP | 1 |
| Sarabhai, T | 1 |
| Karusheva, Y | 1 |
| Burkart, V | 1 |
| Markgraf, DF | 1 |
| Trenkamp, S | 1 |
| Ziegler, D | 1 |
| Szendroedi, J | 1 |
| Roden, M | 2 |
| Neyshaburinezhad, N | 1 |
| Seidabadi, M | 1 |
| Rouini, M | 1 |
| Lavasani, H | 1 |
| Foroumadi, A | 1 |
| Ardakani, YH | 1 |
| Liu, YS | 1 |
| Chen, CN | 1 |
| Chen, ZG | 1 |
| Peng, Y | 1 |
| Lin, XP | 1 |
| Xu, LL | 1 |
| Koufakis, T | 1 |
| Metallidis, S | 1 |
| Zebekakis, P | 1 |
| Ajjan, RA | 1 |
| Kotsa, K | 1 |
| Ren, GF | 2 |
| Xiao, LL | 1 |
| Ma, XJ | 1 |
| Yan, YS | 1 |
| Jiao, PF | 1 |
| Madić, V | 1 |
| Petrović, A | 1 |
| Jušković, M | 1 |
| Jugović, D | 1 |
| Djordjević, L | 1 |
| Stojanović, G | 1 |
| Vasiljević, P | 1 |
| Gürcü, S | 1 |
| Girgin, G | 1 |
| Yorulmaz, G | 1 |
| Kılıçarslan, B | 1 |
| Efe, B | 1 |
| Baydar, T | 1 |
| Hasan, SS | 1 |
| Kow, CS | 1 |
| Bain, A | 1 |
| Kavanagh, S | 1 |
| Merchant, HA | 1 |
| Hadi, MA | 1 |
| Kurozumi, A | 1 |
| Okada, Y | 1 |
| Tanaka, Y | 1 |
| Alrawashdeh, AY | 1 |
| Al Shhab, MA | 1 |
| Zihlif, MA | 1 |
| Yang, D | 1 |
| Yan, J | 1 |
| Deng, H | 1 |
| Yang, X | 1 |
| Luo, S | 1 |
| Zheng, X | 2 |
| Lv, J | 1 |
| Liang, W | 1 |
| Hong, M | 1 |
| Wu, Z | 1 |
| Yao, B | 1 |
| Weng, J | 1 |
| Xu, W | 1 |
| Timmons, JG | 1 |
| Greenlaw, N | 1 |
| Boyle, JG | 2 |
| Chaturvedi, N | 2 |
| Ford, I | 2 |
| Brouwers, MCGJ | 1 |
| Tillin, T | 1 |
| Hramiak, I | 2 |
| Hughes, AD | 2 |
| Jenkins, AJ | 2 |
| Klein, BEK | 1 |
| Klein, R | 2 |
| Ooi, TC | 2 |
| Rossing, P | 4 |
| Stehouwer, CDA | 1 |
| Sattar, N | 2 |
| Colhoun, HM | 3 |
| Petrie, JR | 5 |
| Long, SA | 1 |
| Speake, C | 1 |
| Celotto, S | 1 |
| Pizzol, D | 1 |
| Gasevic, D | 1 |
| Ji, MM | 1 |
| Barnini, T | 1 |
| Solmi, M | 1 |
| Stubbs, B | 1 |
| Smith, L | 1 |
| López Sánchez, GF | 1 |
| Pesolillo, G | 1 |
| Yu, Z | 1 |
| Tzoulaki, I | 1 |
| Theodoratou, E | 1 |
| Ioannidis, JPA | 1 |
| Veronese, N | 1 |
| Demurtas, J | 1 |
| Samocha-Bonet, D | 1 |
| Evans, J | 1 |
| Kowalski, G | 1 |
| Bruce, C | 1 |
| Bonora, E | 1 |
| Cataudella, S | 1 |
| Marchesini, G | 1 |
| Miccoli, R | 1 |
| Vaccaro, O | 1 |
| Fadini, GP | 1 |
| Martini, N | 1 |
| Rossi, E | 1 |
| Lee, YJ | 1 |
| Yoo, S | 1 |
| Yi, S | 1 |
| Kim, S | 1 |
| Lee, C | 1 |
| Cho, J | 1 |
| Ahn, S | 1 |
| Choi, S | 1 |
| Hwang, H | 1 |
| Lee, YA | 1 |
| Shin, CH | 1 |
| Yoon, HJ | 1 |
| Kim, K | 1 |
| Song, E | 1 |
| Choi, JH | 1 |
| Yoo, HW | 1 |
| Kim, YH | 1 |
| Oh, JS | 1 |
| Kang, EA | 1 |
| Baek, GK | 1 |
| Kim, JH | 1 |
| Gourgari, E | 1 |
| Pyle, L | 3 |
| Playford, MP | 1 |
| Ma, J | 1 |
| Mehta, NN | 1 |
| Remaley, AT | 1 |
| Gordon, SM | 1 |
| Azapagasi, E | 1 |
| Yazici, MU | 1 |
| Korucu, A | 1 |
| Sarigul, B | 1 |
| Bozkurt, I | 1 |
| Tasar, M | 1 |
| Elmaogullari, S | 1 |
| Emeksiz, S | 1 |
| Öcgüder, DA | 1 |
| Tseng, CH | 1 |
| Fauchier, G | 1 |
| Bisson, A | 1 |
| Bodin, A | 1 |
| Herbert, J | 1 |
| Angoulvant, D | 1 |
| Ducluzeau, PH | 1 |
| Lip, GYH | 1 |
| Fauchier, L | 1 |
| Staels, F | 1 |
| Moyson, C | 1 |
| Mathieu, C | 2 |
| Lecka-Czernik, B | 1 |
| Schroeder, EB | 1 |
| Xu, S | 1 |
| Goodrich, GK | 1 |
| Nichols, GA | 1 |
| O'Connor, PJ | 1 |
| Steiner, JF | 1 |
| Standl, E | 1 |
| Livingstone, R | 1 |
| Shpakov, AO | 1 |
| Chamberlain, JJ | 1 |
| Kalyani, RR | 1 |
| Leal, S | 1 |
| Rhinehart, AS | 1 |
| Shubrook, JH | 1 |
| Skolnik, N | 1 |
| Snell-Bergeon, JK | 1 |
| Anderson, JJA | 2 |
| Couper, JJ | 2 |
| Giles, LC | 2 |
| Leggett, CE | 1 |
| Gent, R | 3 |
| Coppin, B | 2 |
| Peña, AS | 4 |
| Levesque, C | 1 |
| Reinehr, T | 1 |
| Beysel, S | 1 |
| Unsal, IO | 1 |
| Kizilgul, M | 1 |
| Caliskan, M | 1 |
| Ucan, B | 1 |
| Cakal, E | 1 |
| Meng, H | 1 |
| Zhang, A | 1 |
| Liang, Y | 1 |
| Hao, J | 1 |
| Zhang, X | 1 |
| Lu, J | 1 |
| Naciu, AM | 1 |
| Pozzilli, P | 4 |
| Xin, WX | 1 |
| Fang, L | 1 |
| Fang, QL | 1 |
| Zheng, XW | 1 |
| Ding, HY | 1 |
| Huang, P | 1 |
| Liang, WJ | 1 |
| Zhou, SN | 1 |
| Shan, MR | 1 |
| Wang, XQ | 1 |
| Zhang, M | 1 |
| Chen, Y | 1 |
| Zhang, Y | 1 |
| Wang, SX | 1 |
| Guo, T | 1 |
| Ripoli, C | 1 |
| Pinna, AP | 1 |
| Podda, F | 1 |
| Zanni, R | 1 |
| Tronci, MG | 1 |
| Nurchi, AM | 1 |
| Haslacher, H | 1 |
| Fallmann, H | 1 |
| Waldhäusl, C | 1 |
| Hartmann, E | 1 |
| Wagner, OF | 1 |
| Waldhäusl, W | 1 |
| Quintero Ojeda, JE | 1 |
| Aguilar-Medina, M | 1 |
| Olimón-Andalón, V | 1 |
| García Jau, RA | 1 |
| Ayala Ham, A | 1 |
| Romero Quintana, JG | 1 |
| Silva-Benítez, EL | 1 |
| Sanchez-Schmitz, G | 1 |
| Ramos-Payán, R | 1 |
| Mediani, A | 1 |
| Abas, F | 1 |
| Maulidiani, M | 1 |
| Abu Bakar Sajak, A | 1 |
| Khatib, A | 1 |
| Tan, CP | 1 |
| Ismail, IS | 1 |
| Shaari, K | 1 |
| Ismail, A | 1 |
| Lajis, NH | 1 |
| Zawada, A | 3 |
| Naskręt, D | 3 |
| Burchardt, P | 3 |
| Niedźwiecki, P | 1 |
| Piłaciński, S | 1 |
| Wierusz-Wysocka, B | 3 |
| Grzymisławski, M | 2 |
| Zozulińska-Ziółkiewicz, D | 2 |
| Kirac, CO | 1 |
| Ipekci, SH | 1 |
| Kebapcilar, L | 1 |
| Frandsen, CS | 2 |
| Dejgaard, TF | 2 |
| Madsbad, S | 2 |
| Holst, JJ | 1 |
| Kumar, R | 1 |
| Pilania, RK | 1 |
| Bhatia, A | 1 |
| Dayal, D | 1 |
| Otto-Buczkowska, E | 2 |
| Grzyb, K | 1 |
| Jainta, N | 1 |
| Delkhosh-Kasmaie, F | 1 |
| Farshid, AA | 1 |
| Tamaddonfard, E | 1 |
| Imani, M | 1 |
| Liew, G | 1 |
| Anderson, J | 2 |
| Wong, TY | 1 |
| Roglic, G | 1 |
| Norris, SL | 1 |
| Kalra, S | 1 |
| Khandelwal, D | 1 |
| Ahmed, FW | 2 |
| Bastaman, IT | 1 |
| Crossland, RE | 1 |
| Glanville, M | 2 |
| Lansang, MC | 1 |
| Japelj, M | 1 |
| Juretič, A | 1 |
| Abdelsamia, EM | 1 |
| Khaleel, SA | 1 |
| Balah, A | 1 |
| Abdel Baky, NA | 1 |
| Egan, AM | 1 |
| Brassill, MJ | 1 |
| Brosnan, E | 1 |
| Carmody, L | 1 |
| Clarke, H | 1 |
| Coogan Kelly, C | 1 |
| Culliney, L | 1 |
| Durkan, M | 1 |
| Fenlon, M | 1 |
| Ferry, P | 1 |
| Hanlon, G | 1 |
| Higgins, T | 1 |
| Hoashi, S | 1 |
| Khamis, A | 1 |
| Kinsley, B | 1 |
| Kinsley, T | 1 |
| Kirwan, B | 1 |
| Liew, A | 1 |
| McGurk, C | 1 |
| McHugh, C | 1 |
| Murphy, MS | 1 |
| Murphy, P | 1 |
| O'Halloran, D | 1 |
| O'Mahony, L | 1 |
| O'Sullivan, E | 1 |
| Nolan, M | 1 |
| Peter, M | 1 |
| Roberts, G | 1 |
| Smyth, A | 1 |
| Todd, M | 1 |
| Tuthill, A | 1 |
| Wan Mahmood, WA | 1 |
| Yousif, O | 1 |
| P Dunne, F | 1 |
| Wright, LA | 1 |
| Hirsch, IB | 1 |
| Mendonça, FM | 1 |
| Leitão, MJ | 1 |
| Faria-Costa, G | 1 |
| Pires Da Rosa, G | 1 |
| Almeida, J | 1 |
| Cree-Green, M | 2 |
| Bergman, BC | 1 |
| Cengiz, E | 1 |
| Fox, LA | 1 |
| Hannon, TS | 1 |
| Miller, K | 1 |
| Nathan, B | 1 |
| Kahn, D | 1 |
| Tansey, M | 1 |
| Tichy, E | 1 |
| Tsalikian, E | 1 |
| Wiromrat, P | 1 |
| Bjornstad, P | 1 |
| Roncal, C | 1 |
| Baumgartner, A | 1 |
| Coe, G | 1 |
| Reyes, YG | 1 |
| Schäfer, M | 1 |
| Truong, U | 1 |
| Johnson, RJ | 1 |
| Hafez, M | 1 |
| Musa, N | 1 |
| Elbehairy, S | 1 |
| Atty, SA | 1 |
| Elbarbary, M | 1 |
| Amin, M | 1 |
| Feghali, MN | 1 |
| Umans, JG | 1 |
| Catalano, PM | 1 |
| Nna, VU | 1 |
| Abu Bakar, AB | 1 |
| Ahmad, A | 1 |
| Mohamed, M | 1 |
| Leggett, C | 1 |
| Giles, L | 1 |
| Doogue, M | 1 |
| Couper, J | 2 |
| Andersen, DK | 1 |
| Giampietro, O | 1 |
| Giampietro, C | 1 |
| Bartola, LD | 1 |
| Masoni, MC | 1 |
| Matteucci, E | 1 |
| Scheen, AJ | 1 |
| Thirumalai, A | 1 |
| Holing, E | 1 |
| Brown, Z | 1 |
| Gilliam, LK | 1 |
| Sullivan, T | 1 |
| D'Arcy, B | 1 |
| Olds, T | 1 |
| Tabaczewski, P | 1 |
| Kaczmarek, J | 2 |
| Marcinkaniec, J | 2 |
| Wysocki, H | 2 |
| Garg, SK | 1 |
| Michels, AW | 1 |
| Shah, VN | 1 |
| Blake, R | 1 |
| Trounce, IA | 1 |
| Codner, E | 1 |
| Iñíguez, G | 1 |
| López, P | 1 |
| Mujica, V | 1 |
| Eyzaguirre, FC | 1 |
| Asenjo, S | 1 |
| Torrealba, I | 1 |
| Cassorla, F | 1 |
| Hirata, T | 1 |
| Shimada, A | 3 |
| Morimoto, J | 1 |
| Maruyama, T | 1 |
| Eskens, BJ | 1 |
| Zuurbier, CJ | 1 |
| van Haare, J | 1 |
| Vink, H | 1 |
| van Teeffelen, JW | 1 |
| Chlup, R | 1 |
| Doubravova, B | 1 |
| Bartek, J | 1 |
| Zapletalova, J | 1 |
| Krystynik, O | 1 |
| Prochazka, V | 1 |
| Chow, K | 1 |
| Alam, S | 1 |
| Lindquist, K | 1 |
| Campbell, S | 1 |
| McFann, K | 1 |
| Klingensmith, G | 1 |
| Walravens, P | 1 |
| Warncke, K | 1 |
| Engelsberger, I | 2 |
| Calgaroto, NS | 2 |
| Thomé, GR | 1 |
| da Costa, P | 2 |
| Baldissareli, J | 1 |
| Hussein, FA | 1 |
| Schmatz, R | 1 |
| Rubin, MA | 1 |
| Signor, C | 1 |
| Ribeiro, DA | 1 |
| Carvalho, FB | 1 |
| de Oliveira, LS | 1 |
| Pereira, LB | 2 |
| Morsch, VM | 2 |
| Schetinger, MR | 2 |
| Groop, L | 1 |
| Storm, P | 1 |
| Rosengren, A | 1 |
| Konrad, K | 1 |
| Datz, N | 1 |
| Grulich-Henn, J | 1 |
| Hoertenhuber, T | 1 |
| Knauth, B | 1 |
| Meissner, T | 1 |
| Wiegand, S | 1 |
| Woelfle, J | 1 |
| Holl, RW | 1 |
| Poojary, S | 1 |
| Khatu, S | 1 |
| DeGeeter, M | 1 |
| Williamson, B | 1 |
| Liu, C | 1 |
| Wu, D | 1 |
| Li, P | 1 |
| Dujic, T | 1 |
| Zhou, K | 1 |
| Donnelly, LA | 1 |
| Tavendale, R | 1 |
| Palmer, CN | 1 |
| Pearson, ER | 1 |
| Curry, A | 1 |
| Cardoso, AM | 1 |
| Vieira, JM | 1 |
| Dalenogare, D | 1 |
| Pelinson, LP | 1 |
| Knaś, M | 1 |
| Wołosik, K | 1 |
| Zalewska, A | 1 |
| Mikucka-Niczyporuk, A | 1 |
| Kasacka, I | 1 |
| Niczyporuk, M | 1 |
| Kover, KL | 1 |
| Heruth, DP | 1 |
| Watkins, DJ | 1 |
| Moore, WV | 1 |
| Jackson, K | 1 |
| Zang, M | 1 |
| Clements, MA | 1 |
| Yan, Y | 1 |
| Nwosu, BU | 1 |
| Maranda, L | 1 |
| Cullen, K | 1 |
| Greenman, L | 1 |
| Fleshman, J | 1 |
| McShea, N | 1 |
| Barton, BA | 1 |
| Lee, MM | 1 |
| Basnet, S | 1 |
| Kozikowski, A | 1 |
| Makaryus, AN | 1 |
| Pekmezaris, R | 1 |
| Zeltser, R | 1 |
| Akerman, M | 1 |
| Lesser, M | 1 |
| Wolf-Klein, G | 1 |
| Klinepeter Bartz, S | 1 |
| Libman, IM | 1 |
| Miller, KM | 1 |
| DiMeglio, LA | 1 |
| Bethin, KE | 1 |
| Katz, ML | 1 |
| Shah, A | 1 |
| Simmons, JH | 1 |
| Haller, MJ | 1 |
| Raman, S | 1 |
| Tamborlane, WV | 1 |
| Coffey, JK | 1 |
| Saenz, AM | 1 |
| Beck, RW | 1 |
| Wise, J | 1 |
| Claesen, M | 1 |
| Gillard, P | 1 |
| De Smet, F | 1 |
| Callens, M | 1 |
| De Moor, B | 1 |
| Shigiyama, F | 1 |
| Kumashiro, N | 1 |
| Rikitake, T | 1 |
| Usui, S | 1 |
| Saegusa, M | 1 |
| Kitamura, M | 1 |
| Uchino, H | 1 |
| Hirose, T | 1 |
| Goulis, DG | 1 |
| Schwartz, SS | 1 |
| Jellinger, PS | 1 |
| Herman, ME | 1 |
| Yu, JW | 1 |
| Deng, YP | 1 |
| Han, X | 1 |
| Cai, J | 1 |
| Jiang, GJ | 1 |
| Liatis, S | 1 |
| Dafoulas, GE | 1 |
| Kani, C | 1 |
| Politi, A | 1 |
| Litsa, P | 1 |
| Sfikakis, PP | 1 |
| Makrilakis, K | 1 |
| Sharma, AM | 1 |
| Rider, R | 1 |
| Narayanan, K | 1 |
| Razvi, S | 1 |
| Klupa, T | 1 |
| Rzeźniczak, J | 1 |
| Cusi, K | 1 |
| Sanyal, AJ | 1 |
| Zhang, S | 1 |
| Hoogwerf, BJ | 1 |
| Chang, AM | 1 |
| Jacober, SJ | 2 |
| Bue-Valleskey, JM | 1 |
| Higdon, AN | 1 |
| Bastyr, EJ | 1 |
| Haupt, A | 1 |
| Hartman, ML | 1 |
| Porksen, N | 1 |
| Linnebjerg, H | 1 |
| Garhyan, P | 1 |
| Lam, EC | 1 |
| Knadler, MP | 1 |
| Hoevelmann, U | 1 |
| Plum-Moerschel, L | 1 |
| Watkins, E | 1 |
| Gastaldelli, A | 1 |
| Heise, T | 1 |
| E Klein, B | 1 |
| Stehouwer, CD | 1 |
| Lucas-Herald, AK | 1 |
| Robertson, KJ | 1 |
| Maurizi, AR | 1 |
| Menduni, M | 1 |
| Del Toro, R | 1 |
| Kyanvash, S | 1 |
| Maggi, D | 1 |
| Guglielmi, C | 1 |
| Pantano, AL | 1 |
| Defeudis, G | 1 |
| Fioriti, E | 1 |
| Manfrini, S | 1 |
| Thomas, I | 1 |
| Gregg, B | 1 |
| Sheriba, NA | 1 |
| Ahmed, IZ | 1 |
| Abdelsalam, MM | 1 |
| Eid, YM | 1 |
| Mahdy, MM | 1 |
| Mansour, HK | 1 |
| Al Khalifah, RA | 1 |
| Alnhdi, A | 1 |
| Alghar, H | 1 |
| Alanazi, M | 1 |
| Florez, ID | 1 |
| Lund, SS | 2 |
| Tarnow, L | 2 |
| Astrup, AS | 2 |
| Hovind, P | 2 |
| Jacobsen, PK | 2 |
| Alibegovic, AC | 2 |
| Parving, I | 2 |
| Pietraszek, L | 2 |
| Frandsen, M | 2 |
| Parving, HH | 2 |
| Vaag, AA | 2 |
| Abdelghaffar, S | 1 |
| Attia, AM | 1 |
| Pang, TT | 1 |
| Narendran, P | 1 |
| Jung, EY | 1 |
| Cho, HS | 1 |
| Seo, JW | 1 |
| Kim, DW | 1 |
| Kim, HJ | 1 |
| Chang, SH | 1 |
| Park, DJ | 1 |
| Jacobsen, IB | 1 |
| Henriksen, JE | 1 |
| Beck-Nielsen, H | 1 |
| Cernea, S | 1 |
| Buzzetti, R | 1 |
| Nowowiejska, B | 1 |
| Jarosz-Chobot, P | 1 |
| Stańczyk, J | 1 |
| Vella, S | 2 |
| Buetow, L | 2 |
| Royle, P | 2 |
| Livingstone, S | 2 |
| Ng, JM | 1 |
| Mellor, DD | 1 |
| Masson, EA | 1 |
| Allan, BJ | 1 |
| Monte, SV | 1 |
| Schentag, JJ | 1 |
| Adelman, MH | 1 |
| Paladino, JA | 1 |
| Lebovitz, HE | 1 |
| Schatz, H | 2 |
| Han, B | 1 |
| You, L | 1 |
| Lee, JP | 1 |
| Chen, W | 1 |
| Wu, HT | 1 |
| Lin, KC | 1 |
| Cheng, JT | 1 |
| Jermendy, G | 1 |
| Brufani, C | 1 |
| Fintini, D | 1 |
| Nobili, V | 1 |
| Patera, PI | 1 |
| Cappa, M | 1 |
| Brufani, M | 1 |
| Cigarrán, S | 1 |
| Rodriguez, ML | 1 |
| Pousa, M | 1 |
| Menéndez, H | 1 |
| Mendez, MJ | 1 |
| Pernicova, I | 1 |
| Prasai, MJ | 1 |
| Close, EJ | 1 |
| Drury, K | 1 |
| Gilbey, SG | 1 |
| Brewster, JA | 1 |
| Scott, EM | 1 |
| Spaans, EA | 1 |
| Kleefstra, N | 1 |
| van Hateren, KJ | 1 |
| Aanstoot, HJ | 1 |
| Bilo, HJ | 1 |
| Brand, PL | 1 |
| Pandey, A | 1 |
| Forte, V | 1 |
| Abdallah, M | 1 |
| Alickaj, A | 1 |
| Mahmud, S | 1 |
| Asad, S | 1 |
| McFarlane, SI | 1 |
| Shigihara, T | 2 |
| Okubo, Y | 2 |
| Katsuki, T | 1 |
| Yamada, Y | 1 |
| Oikawa, Y | 2 |
| Su, H | 1 |
| Velly, AM | 1 |
| Salah, MH | 1 |
| Benarroch, M | 1 |
| Trifiro, M | 1 |
| Schipper, HM | 1 |
| Gornitsky, M | 1 |
| Mathiesen, ER | 1 |
| Ringholm, L | 1 |
| Damm, P | 1 |
| Ballas, J | 1 |
| Moore, TR | 1 |
| Ramos, GA | 1 |
| Naha, K | 1 |
| Vivek, G | 1 |
| Dasari, S | 1 |
| Prabhu, M | 1 |
| George, P | 1 |
| McCrimmon, RJ | 1 |
| Aragno, M | 1 |
| Mastrocola, R | 1 |
| Ghé, C | 1 |
| Arnoletti, E | 1 |
| Bassino, E | 1 |
| Alloatti, G | 1 |
| Muccioli, G | 1 |
| Pitocco, D | 1 |
| Zaccardi, F | 1 |
| Tarzia, P | 1 |
| Milo, M | 1 |
| Scavone, G | 1 |
| Rizzo, P | 1 |
| Pagliaccia, F | 1 |
| Nerla, R | 1 |
| Di Franco, A | 1 |
| Manto, A | 1 |
| Rocca, B | 1 |
| Lanza, GA | 1 |
| Crea, F | 1 |
| Ghirlanda, G | 1 |
| Krzymień, J | 1 |
| Karnafel, W | 1 |
| Vignini, A | 1 |
| Giulietti, A | 1 |
| Nanetti, L | 1 |
| Raffaelli, F | 1 |
| Mazzanti, L | 1 |
| Provinciali, L | 1 |
| Montagnani, A | 1 |
| Gonnelli, S | 1 |
| Dove, A | 1 |
| Meyer, L | 2 |
| Bohme, P | 1 |
| Delbachian, I | 1 |
| Lehert, P | 1 |
| Cugnardey, N | 1 |
| Drouin, P | 1 |
| Guerci, B | 2 |
| Solignac, M | 1 |
| Hamilton, J | 1 |
| Cummings, E | 1 |
| Zdravkovic, V | 1 |
| Finegood, D | 1 |
| Daneman, D | 3 |
| Faichney, JD | 1 |
| Tate, PW | 1 |
| Varo, N | 1 |
| Vicent, D | 1 |
| Libby, P | 1 |
| Nuzzo, R | 1 |
| Calle-Pascual, AL | 1 |
| Bernal, MR | 1 |
| Fernández-Cruz, A | 1 |
| Veves, A | 1 |
| Jarolim, P | 1 |
| Varo, JJ | 1 |
| Goldfine, A | 1 |
| Horton, E | 1 |
| Schönbeck, U | 1 |
| Gunton, JE | 1 |
| Twigg, SM | 1 |
| Särnblad, S | 1 |
| Kroon, M | 1 |
| Aman, J | 1 |
| Aldasouqi, SA | 1 |
| Duick, DS | 1 |
| Bloomgarden, ZT | 2 |
| Tankova, T | 1 |
| Podgorski, GP | 1 |
| Lacigová, S | 2 |
| Rusavý, Z | 2 |
| Kyselová, P | 2 |
| Jankovec, Z | 2 |
| Kárová, R | 1 |
| Cechurová, D | 1 |
| Ley, SC | 1 |
| Preckel, B | 1 |
| Schlack, W | 1 |
| Urakami, T | 1 |
| Morimoto, S | 1 |
| Owada, M | 1 |
| Harada, K | 1 |
| Strowig, SM | 1 |
| Raskin, P | 1 |
| Rachmiel, M | 1 |
| Perlman, K | 1 |
| Jacobson-Dickman, E | 1 |
| Levitsky, L | 1 |
| Hassouna, A | 1 |
| Loubani, M | 1 |
| Matata, BM | 1 |
| Fowler, A | 1 |
| Standen, NB | 1 |
| Galiñanes, M | 1 |
| Sadri, H | 1 |
| MacKeigan, LD | 1 |
| Leiter, LA | 1 |
| Einarson, TR | 1 |
| Khan, AS | 1 |
| McLoughney, CR | 1 |
| Ahmed, AB | 1 |
| Lee, MJ | 1 |
| Feliers, D | 1 |
| Mariappan, MM | 1 |
| Sataranatarajan, K | 1 |
| Mahimainathan, L | 1 |
| Musi, N | 1 |
| Foretz, M | 1 |
| Viollet, B | 1 |
| Weinberg, JM | 1 |
| Choudhury, GG | 1 |
| Kasinath, BS | 1 |
| Kanazawa, Y | 1 |
| Johnson, JA | 1 |
| Pohar, SL | 1 |
| Secnik, K | 1 |
| Yurgin, N | 1 |
| Hirji, Z | 1 |
| Moon, RJ | 1 |
| Bascombe, LA | 1 |
| Holt, RI | 1 |
| Wasikowa, RB | 1 |
| Basiak, A | 1 |
| Aumiller, J | 1 |
| Zeyfang, A | 1 |
| Gabbay, Mde A | 1 |
| Joffroy-Lavieuville, M | 1 |
| Noël, M | 1 |
| Bailey, CJ | 1 |
| Mynett, KJ | 1 |
| Estrada, DE | 1 |
| Elliott, E | 1 |
| Zinman, B | 1 |
| Poon, I | 1 |
| Klip, A | 1 |
| Handberg, A | 1 |
| Kayser, L | 1 |
| Høyer, PE | 1 |
| Voldstedlund, M | 1 |
| Hansen, HP | 1 |
| Vinten, J | 1 |
| Golay, A | 1 |
| Guillet-Dauphiné, N | 1 |
| Fendel, A | 1 |
| Juge, C | 1 |
| Assal, JP | 1 |
| Jurovich, MR | 1 |
| Wooldridge, JD | 1 |
| Force, RW | 1 |
| Daniel, JR | 1 |
| Hagmeyer, KO | 1 |
| Beales, PE | 1 |
| Giorgini, A | 1 |
| Annovazzi, A | 1 |
| Signore, A | 1 |
| Parlapiano, C | 1 |
| Pinhas-Hamiel, O | 1 |
| Zeitler, P | 1 |
| Sarlis, NJ | 1 |
| Weil, SJ | 1 |
| Nelson, LM | 1 |
| Lysy, J | 1 |
| Israeli, E | 1 |
| Goldin, E | 1 |
| Petersen, KF | 1 |
| Shulman, GI | 1 |
| Bo-Abbas, YY | 1 |
| Brousseau, VJ | 1 |
| Benjamin, SM | 1 |
| Valdez, R | 1 |
| Vinicor, F | 1 |
| Winkler, G | 1 |
| Jonatha, EM | 1 |
| Pfeiffer, EF | 1 |
| Janssen, M | 1 |
| Rillaerts, E | 1 |
| De Leeuw, I | 1 |
| Slama, G | 2 |
| Rapin, JR | 1 |
| Lespinasse, C | 1 |
| Yoa, R | 1 |
| Wiernsperger, N | 1 |
| Gill, G | 1 |
| Gin, H | 2 |
| Freyburger, G | 1 |
| Boisseau, M | 1 |
| Aubertin, J | 2 |
| Rizkalla, SW | 1 |
| Elgrably, F | 1 |
| Tchobroutsky, G | 1 |
| Isnard, F | 1 |
| Ibagnez, A | 1 |
| Andre, P | 1 |
| Laakso, M | 1 |
| Voutilainen, E | 1 |
| Sarlund, H | 1 |
| Aro, A | 1 |
| Pyörälä, K | 1 |
| Penttilä, I | 1 |
| Fossati, P | 1 |
| Fontaine, P | 1 |
| Beuscart, R | 1 |
| Messerchmitt, C | 1 |
| Brottier, E | 1 |
| Tattersall, RB | 1 |
| Levy, JM | 1 |
| Stoll, C | 1 |
| Amar, U | 1 |
| Thierry, R | 1 |
| Segura, N | 1 |
| Bouaziz, M | 1 |
| Haese, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Metformin Use on Mortality in Diabetic and Non Diabetic Patients With Sepsis and Septic Shock.[NCT05572060] | 75 participants (Anticipated) | Interventional | 2022-12-01 | Not yet recruiting | |||
| Prospective Study on Diabetes Mellitus and Its Complications in Newly Diagnosed Adult Patients[NCT01055093] | 2,000 participants (Anticipated) | Observational | 2005-09-30 | Recruiting | |||
| The Effect of Simvastatin on Bone Density in Postmenopausal Women With Type 2 Diabetes: a Double-blind, Randomized Active-comparator (Ezetimibe) Controlled Clinical Trial[NCT05613400] | Phase 4 | 240 participants (Anticipated) | Interventional | 2022-04-13 | Enrolling by invitation | ||
| Cyclophosphamide in the Treatment of Panniculitis Associated Acquired Lipodystrophy Syndrome With Type 1 Diabetes[NCT03936829] | 10 participants (Anticipated) | Interventional | 2019-04-28 | Recruiting | |||
| The Effects of Empagliflozin on Functional and Structural Arterial Wall Characteristics[NCT03639545] | Phase 4 | 120 participants (Anticipated) | Interventional | 2018-03-01 | Recruiting | ||
| Metformin Therapy for Overweight Adolescents With Type 1 Diabetes (T1D)--Insulin Clamp Ancillary Study for Assessment of Insulin Resistance[NCT02045290] | Phase 3 | 37 participants (Actual) | Interventional | 2014-01-31 | Completed | ||
| Genetics of Diabetes Audit and Research in Tayside Scotland (DOLORisk Dundee)[NCT02783469] | 1,915 participants (Actual) | Observational | 2004-10-31 | Completed | |||
| Impact of OCT1 Genotype and OCT1 Inhibiting Drugs on an Individual's Tolerance of Metformin[NCT02586636] | Phase 4 | 61 participants (Actual) | Interventional | 2016-03-31 | Completed | ||
| Glycemic Control in Children and Adolescents With Double Diabetes: Trial of Optimized Insulin-Metformin Regimen[NCT01334125] | Phase 3 | 28 participants (Actual) | Interventional | 2011-02-28 | Completed | ||
| A Randomized Trial of Metformin as Adjunct Therapy for Overweight Adolescents With Type 1 Diabetes[NCT01881828] | Phase 3 | 164 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| A Pilot Study of D-Chiro-Inositol Plus Folic Acid in Overweight Patients With Type 1 Diabetes[NCT02730949] | Phase 3 | 26 participants (Actual) | Interventional | 2014-03-31 | Completed | ||
| Effect of Metformin On Glycaemic Control and Non-Glycaemic Cardiovascular Risk-Factors in Patients With Type-1 Diabetes, With Long-Standing Inadequate Glycaemic Control by Insulin and Diet[NCT00118937] | Phase 4 | 100 participants (Actual) | Interventional | 2003-12-31 | Completed | ||
| Liraglutide in the Treatment of Type 1 Diabetes Mellitus[NCT01722266] | Phase 3 | 72 participants (Actual) | Interventional | 2012-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Comparison of the baseline-adjusted differences in adiponectin/leptin ratio over time between the metformin and the placebo groups. The reported values represented mean adjusted for baseline values, age, gender, and BMI using repeated measures ANOVA (General Linear Model). (NCT01334125)
Timeframe: Baseline, 3mo, 6 mo, and 9 months
| Intervention | ratio (Mean) |
|---|---|
| Metformin | 2.0 |
| Placebo | 1.2 |
Comparison of the baseline-adjusted differences in total cholesterol/high density cholesterol index over time between the metformin and the placebo groups. The reported values represented means adjusted for baseline values, age, gender, and BMI using repeated measures ANOVA (General Linear Model). (NCT01334125)
Timeframe: Baseline, 3mo, 6mo, and 9 months
| Intervention | ratio (Mean) |
|---|---|
| Metformin | 3.5 |
| Placebo | 4 |
Comparison of the baseline-adjusted differences in HbA1c between the metformin and placebo groups during the trial. Hemoglobin A1c is a marker of glycemic control. The reported values represented means adjusted for baseline values, age, gender, and BMI using repeated measures ANOVA (General Linear Model). (NCT01334125)
Timeframe: Baseline, 3mo, 6mo, and 9 months
| Intervention | percentage of HbA1c (Mean) |
|---|---|
| Metformin | 9.46 |
| Placebo | 9.85 |
Comparison of the occurrence of hypoglycemic event requiring a third party assistance (major hypoglycemia) per subject during the study, and minor hypoglycemia (plasma glucose of <60 mg/dL or no measurement), as well as nocturnal hypoglycemia (plasma glucose of ≤60 mg/dL between 11PM and 6AM). (NCT01334125)
Timeframe: 12 months
| Intervention | participants (Number) | ||
|---|---|---|---|
| Major hypoglycemia | Minor hypoglycemia | Nocturnal hypoglycemia | |
| Metformin | 1 | 3 | 2 |
| Placebo | 0 | 2 | 2 |
Change in percent body fat (NCT01881828)
Timeframe: 0-26 weeks
| Intervention | percentage of change (Mean) |
|---|---|
| Metformin | -0 |
| Oral Placebo | 1 |
(NCT01881828)
Timeframe: 0-26 weeks
| Intervention | percentile (Mean) |
|---|---|
| Metformin | -1 |
| Oral Placebo | 1 |
(NCT01881828)
Timeframe: 0-26 weeks
| Intervention | insulin per kg (Mean) |
|---|---|
| Metformin | -0.1 |
| Oral Placebo | -0.0 |
(NCT01881828)
Timeframe: 0-26 weeks
| Intervention | centimeters (Mean) |
|---|---|
| Metformin | -0 |
| Oral Placebo | 1 |
(NCT01881828)
Timeframe: 0-26 weeks
| Intervention | mm Hg (Mean) | |
|---|---|---|
| Change in Systolic | Change in Diastolic | |
| Metformin | 0 | 0 |
| Oral Placebo | -0 | 0 |
Hemoglobin A1c is a measure of glycemic control over approximately the past 3 months (NCT01881828)
Timeframe: 0-26 weeks
| Intervention | percentage (Mean) | |
|---|---|---|
| HbA1c | Change from Baseline to 26 Weeks | |
| Metformin | 9.0 | 0.2 |
| Oral Placebo | 8.9 | 0.2 |
Hemoglobin A1c is a measure of glycemic control over approximately the past 3 months (NCT01881828)
Timeframe: 0-26 weeks
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| HbA1c Decrease ≥0.5% | HbA1c Increase ≥0.5% | HbA1c <7.5% | |
| Metformin | 19 | 44 | 3 |
| Oral Placebo | 18 | 35 | 4 |
(NCT01881828)
Timeframe: 0-26 weeks
| Intervention | mg/dL (Mean) | ||||
|---|---|---|---|---|---|
| Change in LDL | Change in VLDL | Change in HDL | Change in Triglycerides | Change in Total Cholesterol | |
| Metformin | -6 | -0 | -0 | 4 | -5 |
| Oral Placebo | 2 | 1 | -1 | 6 | 3 |
(NCT01722266)
Timeframe: 12 weeks
| Intervention | grams (Mean) |
|---|---|
| Placebo | -13.4 |
| Liraglutide 1.8mg | -46.4 |
| Liraglutide 1.2mg | -47.6 |
| Liraglutide 0.6 mg | -23.7 |
(NCT01722266)
Timeframe: Baseline and 12 weeks
| Intervention | Kg (Mean) |
|---|---|
| Placebo | -0.3 |
| Liraglutide 1.8mg | -4.8 |
| Liraglutide 1.2mg | -5.0 |
| Liraglutide 0.6 mg | -2.7 |
(NCT01722266)
Timeframe: Baseline and 12 Weeks
| Intervention | Percent (Mean) |
|---|---|
| Placebo | -0.30 |
| Liraglutide 1.8mg | -0.42 |
| Liraglutide 1.2mg | -0.78 |
| Liraglutide 0.6 mg | -0.26 |
The primary endpoint of the study is to detect a difference from baseline in mean weekly blood glucose concentrations before and after 12 weeks of treatment in each of the Liraglutide groups. (NCT01722266)
Timeframe: 12 Weeks
| Intervention | mg/dl (Mean) |
|---|---|
| Placebo | 1 |
| Liraglutide 1.8mg | -10 |
| Liraglutide 1.2mg | -10 |
| Liraglutide 0.6 mg | -0.3 |
Total insulin dose = Basal insulin dose plus bolus insulin dose. (NCT01722266)
Timeframe: Baseline and 12 weeks
| Intervention | Units (Mean) |
|---|---|
| Placebo | -3.4 |
| Liraglutide 1.8mg | -10 |
| Liraglutide 1.2mg | -12.1 |
| Liraglutide 0.6 mg | -2.8 |
61 reviews available for metformin and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
Effect and Safety of Adding Metformin to Insulin Therapy in Treating Adolescents With Type 1 Diabetes Mellitus: An Updated Meta-Analysis of 10 Randomized Controlled Trials.
Topics: Adolescent; Diabetes Mellitus, Type 1; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agent | 2022 |
The National Clinical Care Commission Report to Congress: Leveraging Federal Policies and Programs to Prevent Diabetes in People With Prediabetes.
Topics: Adult; Aged; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glucose; Humans; Medicare; Metfor | 2023 |
Systematic literature review and network meta-analysis of sodium-glucose co-transporter inhibitors vs metformin as add-on to insulin in type 1 diabetes.
Topics: Clinical Trials, Phase III as Topic; Clinical Trials, Phase IV as Topic; Diabetes Mellitus, Type 1; | 2020 |
Metformin: Up to Date.
Topics: Antineoplastic Agents; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Humans; Hypergl | 2020 |
Reducing Type 1 Diabetes Mortality: Role for Adjunctive Therapies?
Topics: Diabetes Mellitus, Type 1; Humans; Hypoglycemic Agents; Incretins; Metformin; Outcome Assessment, He | 2020 |
Vascular and metabolic effects of metformin added to insulin therapy in patients with type 1 diabetes: A systematic review and meta-analysis.
Topics: Diabetes Mellitus, Type 1; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Metformi | 2020 |
Pharmacotherapeutic considerations for the management of diabetes mellitus among hospitalized COVID-19 patients.
Topics: Adrenal Cortex Hormones; Blood Glucose; Comorbidity; COVID-19; Deprescriptions; Diabetes Mellitus, T | 2021 |
Metformin and health outcomes: An umbrella review of systematic reviews with meta-analyses.
Topics: Body Mass Index; Cardiovascular Diseases; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Fema | 2021 |
The Relationship between Diabetes Mellitus and Gastric Cancer and the Potential Benefits of Metformin: An Extensive Review of the Literature.
Topics: Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Gastrectomy; Humans; Hyperglycemia; Hy | 2021 |
Diabetes, bone and glucose-lowering agents: basic biology.
Topics: Animals; Biomarkers; Blood Flow Velocity; Blood Glucose; Bone and Bones; Bone Density; Diabetes Mell | 2017 |
A new perspective on metformin therapy in type 1 diabetes.
Topics: Atherosclerosis; Cholesterol; Diabetes Mellitus, Type 1; Humans; Hypoglycemic Agents; Metformin | 2017 |
[Pharmacological approaches for correction of thyroid dysfunctions in diabetes mellitus].
Topics: Antioxidants; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Gene Expression; Humans; Hypothy | 2017 |
Diabetes: Cardiovascular benefits of metformin in T1DM.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 1; Humans; Hypoglycemic Agents; Metformin | 2017 |
Management of Diabetes in Children and Adolescents.
Topics: Adolescent; Child; Child Welfare; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Drug Therapy | 2017 |
Effect of metformin on glycaemic control in patients with type 1 diabetes: A meta-analysis of randomized controlled trials.
Topics: Diabetes Mellitus, Type 1; Humans; Hypoglycemic Agents; Metformin; Prognosis; Randomized Controlled | 2018 |
Novel blood glucose lowering therapies for managing type 1 diabetes in paediatric patients.
Topics: Blood Glucose; Child; Diabetes Mellitus, Type 1; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like P | 2018 |
Effect of hypoglycemic agents on survival outcomes of lung cancer patients with diabetes mellitus: A meta-analysis.
Topics: Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Lung Neo | 2018 |
Non-insulin pharmacological therapies for treating type 1 diabetes.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 1; Dipeptidyl-Peptidase IV Inhibitors; Gastrointes | 2018 |
Polycystic ovary syndrome (PCOS) and the accompanying disorders of glucose homeostasis among girls at the time of puberty.
Topics: Adolescent; Diabetes Mellitus, Type 1; Female; Homeostasis; Humans; Hyperinsulinism; Hypoglycemic Ag | 2018 |
Thyrovigilance in diabetes; glucovigilance in thyroidology.
Topics: Comorbidity; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Humans; Hypert | 2018 |
Non-insulin treatments for Type 1 diabetes: critical appraisal of the available evidence and insight into future directions.
Topics: Diabetes Mellitus, Type 1; Dipeptidyl-Peptidase IV Inhibitors; Endocrinology; Humans; Hypoglycemic A | 2019 |
Drugs to Control Diabetes During Pregnancy.
Topics: Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Glycated Hemogl | 2019 |
Diabetes and cancer: placing the association in perspective.
Topics: Blood Glucose; Carcinoma, Pancreatic Ductal; Cell Transformation, Neoplastic; Diabetes Complications | 2013 |
[Limited add-on value of oral glucose-lowering agents in type 1 diabetes].
Topics: Administration, Oral; Animals; Diabetes Mellitus, Type 1; Drug Combinations; Enzyme Inhibitors; Glyc | 2013 |
Use of non-insulin therapies for type 1 diabetes.
Topics: Allylamine; Animals; Blood Glucose; Bromocriptine; Cardiovascular Diseases; Colesevelam Hydrochlorid | 2013 |
Mitochondrial dysfunction and complications associated with diabetes.
Topics: Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Humans; Hyperglycemia; Insulin; Metformin; Mit | 2014 |
Alternative Agents in Type 1 Diabetes in Addition to Insulin Therapy: Metformin, Alpha-Glucosidase Inhibitors, Pioglitazone, GLP-1 Agonists, DPP-IV Inhibitors, and SGLT-2 Inhibitors.
Topics: Diabetes Mellitus, Type 1; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Glycoside Hy | 2016 |
Efficacy and safety of metformin for patients with type 1 diabetes mellitus: a meta-analysis.
Topics: Blood Glucose; Diabetes Mellitus, Type 1; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin | 2015 |
Insulin resistance, role of metformin and other non-insulin therapies in pediatric type 1 diabetes.
Topics: Adolescent; Blood Glucose; Child; Diabetes Mellitus, Type 1; Humans; Hypoglycemic Agents; Insulin; I | 2016 |
Non-insulin drugs to treat hyperglycaemia in type 1 diabetes mellitus.
Topics: Diabetes Mellitus, Type 1; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide-1 Receptor; Hum | 2016 |
Obviating much of the need for insulin therapy in type 2 diabetes mellitus: A re-assessment of insulin therapy's safety profile.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 1; Diabetes | 2016 |
Metformin; a review of its history and future: from lilac to longevity.
Topics: Child; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; History, 17th Century; History, 18th Ce | 2017 |
The effect of adding metformin to insulin therapy for type 1 diabetes mellitus children: A systematic review and meta-analysis.
Topics: Adolescent; Adult; Child; Diabetes Mellitus, Type 1; Drug Monitoring; Drug Therapy, Combination; Evi | 2017 |
Metformin added to insulin therapy for type 1 diabetes mellitus in adolescents.
Topics: Adolescent; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insul | 2009 |
Addressing insulin resistance in Type 1 diabetes.
Topics: Blood Glucose; Diabetes Mellitus, Type 1; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin | 2008 |
Beta-cell protection and therapy for latent autoimmune diabetes in adults.
Topics: Adult; Age of Onset; Chaperonin 60; Diabetes Mellitus, Type 1; Glutamate Decarboxylase; Humans; Hypo | 2009 |
[Could oral antidiabetic agents be useful in the management of different types of diabetes and syndromes of insulin resistance in children and adolescents?].
Topics: Administration, Oral; Adolescent; Child; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Femal | 2009 |
The use of metformin in type 1 diabetes: a systematic review of efficacy.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Humans; Hypoglycemic | 2010 |
Adjunct therapy for type 1 diabetes mellitus.
Topics: Amyloid; Carbohydrate Metabolism; Diabetes Mellitus, Type 1; Digestion; Drug Therapy, Combination; E | 2010 |
[New clinical data with metformin therapy in patients with diabetes mellitus].
Topics: Administration, Oral; Adult; Aged; Biomarkers; Clinical Trials as Topic; Diabetes Complications; Dia | 2010 |
Use of metformin in pediatric age.
Topics: Adolescent; Antipsychotic Agents; Child; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Fatty | 2011 |
[Metformin in adolescents and adults with type 1 diabetes mellitus: not evidence-based].
Topics: Adolescent; Adult; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Evidence-Based Medicine; Fe | 2011 |
Diabetes mellitus and the risk of cancer.
Topics: Diabetes Complications; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Humans; Hypoglycemic A | 2011 |
Management of diabetes in pregnancy.
Topics: Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Glyburide; Huma | 2012 |
Potential role of non-insulin adjunct therapy in Type 1 diabetes.
Topics: Blood Glucose; Body Weight; C-Peptide; Diabetes Mellitus, Type 1; Dipeptidyl-Peptidase IV Inhibitors | 2013 |
Alzheimer's disease and diabetes: new insights and unifying therapies.
Topics: Alzheimer Disease; Amyloid Precursor Protein Secretases; Aspartic Acid Endopeptidases; Diabetes Mell | 2013 |
Antidiabetic therapy effects on bone metabolism and fracture risk.
Topics: Aging; Animals; Bone Density; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-Pepti | 2013 |
Glycemic treatment: Control of glycemia.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glucose Intolerance; H | 2004 |
Current indications for metformin therapy.
Topics: Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin R | 2003 |
[Perioperative treatment of patients with Diabetes mellitus].
Topics: Anesthesia; Blood Transfusion; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type | 2005 |
Combination therapy using metformin or thiazolidinediones and insulin in the treatment of diabetes mellitus.
Topics: Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemi | 2005 |
Insulin analogues in children and teens with type 1 diabetes: advantages and caveats.
Topics: Adolescent; Amyloid; Child; Diabetes Mellitus, Type 1; Glucagon-Like Peptide 1; Humans; Hypoglycemic | 2005 |
Progress in the treatment of diabetes type 1 and 2.
Topics: Animals; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Disease Progression; Female; Genetic | 2007 |
[Specific aspects of diabetes management in the elderly].
Topics: Acarbose; Age Factors; Aged; Aged, 80 and over; Diabetes Complications; Diabetes Mellitus; Diabetes | 2005 |
[Adjunctive therapies to glycaemic control of type 1 diabetes mellitus].
Topics: Acarbose; Amyloid; Blood Glucose; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Gastrointest | 2008 |
[Action of metformin at and beyond insulin receptors. Studies in humans].
Topics: Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Erythrocytes; Humans; Insulin; Metformin; Mono | 1983 |
The insulin-sparing effect of metformin in insulin-treated diabetic patients.
Topics: Blood Glucose; Blood Pressure; Controlled Clinical Trials as Topic; Diabetes Mellitus, Type 1; Drug | 1995 |
Metformin and insulin: is there a role for combination therapy?
Topics: Cross-Over Studies; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Humans; Hypoglycemic Agent | 1997 |
Nuclear magnetic resonance studies of hepatic glucose metabolism in humans.
Topics: Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Fasting; Glucose; Glycogen; Humans; Hyperglyce | 2001 |
The insulin sparing effect of metformin in insulin-treated diabetic patients.
Topics: Diabetes Mellitus, Type 1; Drug Synergism; Humans; Insulin; Insulin Secretion; Islets of Langerhans; | 1991 |
Practical management of diabetes in the tropics.
Topics: Blood Glucose; Chlorpropamide; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Glucose | 1990 |
46 trials available for metformin and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
Benefits of metformin add-on insulin therapy (MAIT) for HbA1c and lipid profile in adolescents with type 1 diabetes mellitus: preliminary report from a double-blinded, placebo-controlled, randomized clinical trial.
Topics: Adolescent; Adult; Blood Glucose; Child; Cholesterol; Diabetes Mellitus, Type 1; Diabetes Mellitus, | 2022 |
Effect of metformin as an add-on therapy on neuregulin-4 levels and vascular-related complications in adolescents with type 1 diabetes: A randomized controlled trial.
Topics: Adolescent; Atherosclerosis; Blood Glucose; C-Reactive Protein; Cardiovascular Diseases; Carotid Int | 2022 |
Empagliflozin-Metformin Combination Has Antioxidative and Anti-Inflammatory Properties that Correlate with Vascular Protection in Adults with Type 1 Diabetes.
Topics: Adult; Advanced Oxidation Protein Products; Anti-Inflammatory Agents; Antioxidants; Benzhydryl Compo | 2022 |
Combination therapy with saxagliptin and vitamin D for the preservation of β-cell function in adult-onset type 1 diabetes: a multi-center, randomized, controlled trial.
Topics: Adult; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Drug Therapy, | 2023 |
Effects of metformin on glycaemic variability in combination with insulin in overweight/obese patients with type 1 diabetes.
Topics: Adolescent; Aged; Blood Glucose; Diabetes Mellitus, Type 1; Glycated Hemoglobin; Humans; Hypoglycemi | 2023 |
Effect of Metformin as adjunct therapy with insulin in adolescent Pakistani people with type 1 diabetes.
Topics: Adolescent; Blood Glucose; Child; Diabetes Mellitus, Type 1; Glycated Hemoglobin; Humans; Insulin; M | 2023 |
Effects of Metformin Added to Insulin in Adolescents with Type 1 Diabetes: An Exploratory Crossover Randomized Trial.
Topics: Adolescent; Age Factors; Blood Glucose; Child; China; Cross-Over Studies; Diabetes Mellitus, Type 1; | 2020 |
Metformin and carotid intima-media thickness in never-smokers with type 1 diabetes: The REMOVAL trial.
Topics: Carotid Arteries; Carotid Intima-Media Thickness; Diabetes Mellitus, Type 1; Double-Blind Method; Hu | 2021 |
Insulin resistance in type 1 diabetes managed with metformin (INTIMET): Study protocol of a double-blind placebo-controlled, randomised trial.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 1; Double-Blind Method; Fasting; Female; Glucose Clamp | 2021 |
Effect of metformin on the high-density lipoprotein proteome in youth with type 1 diabetes.
Topics: Adolescent; Child; Cholesterol, HDL; Diabetes Mellitus, Type 1; Double-Blind Method; Humans; Lipopro | 2021 |
Effect of Metformin on Vascular Function in Children With Type 1 Diabetes: A 12-Month Randomized Controlled Trial.
Topics: Adolescent; Blood Vessels; Brachial Artery; Cardiovascular Diseases; Child; Diabetes Mellitus, Type | 2017 |
Metformin added to intensive insulin therapy improves metabolic control in patients with type 1 diabetes and excess body fat.
Topics: Adipose Tissue; Adolescent; Adult; Body Mass Index; Diabetes Mellitus, Type 1; Drug Therapy, Combina | 2018 |
Early atherosclerosis is associated with retinal microvascular changes in adolescents with type 1 diabetes.
Topics: Adolescent; Age of Onset; Atherosclerosis; Child; Cross-Sectional Studies; Diabetes Mellitus, Type 1 | 2018 |
Empagliflozin on top of metformin treatment improves arterial function in patients with type 1 diabetes mellitus.
Topics: Adult; Aged; Arteries; Benzhydryl Compounds; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 1; D | 2018 |
Metformin Improves Peripheral Insulin Sensitivity in Youth With Type 1 Diabetes.
Topics: Adipose Tissue; Adolescent; Adult; Blood Glucose; Child; Diabetes Mellitus, Type 1; Double-Blind Met | 2019 |
Serum uromodulin inversely associates with aortic stiffness in youth with type 1 diabetes: A brief report from EMERALD study.
Topics: Adolescent; Adult; Aorta; Biomarkers; Cardiovascular Diseases; Child; Diabetes Mellitus, Type 1; Dia | 2019 |
Adherence to metformin is reduced during school holidays and weekends in children with type 1 diabetes participating in a randomised controlled trial.
Topics: Adolescent; Adolescent Behavior; Child; Diabetes Mellitus, Type 1; Double-Blind Method; Female; Glyc | 2019 |
Sitagliptin as add-on therapy in insulin deficiency: biomarkers of therapeutic efficacy respond differently in type 1 and type 2 diabetes.
Topics: Adult; Aged; Biomarkers; Blood Glucose; Body Weight; Cholesterol, LDL; Diabetes Mellitus, Type 1; Di | 2013 |
Does metformin improve vascular health in children with type 1 diabetes? Protocol for a one year, double blind, randomised, placebo controlled trial.
Topics: Adolescent; Cardiovascular Diseases; Carotid Intima-Media Thickness; Child; Diabetes Mellitus, Type | 2013 |
Metformin added to intensive insulin therapy reduces plasma levels of glycated but not oxidized low‑density lipoprotein in young patients with type 1 diabetes and obesity in comparison with insulin alone: a pilot study.
Topics: Adult; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Female; Glycation End Products, Advance | 2013 |
Metformin for the treatment of hyperandrogenism in adolescents with type 1 diabetes mellitus.
Topics: 17-alpha-Hydroxyprogesterone; Adolescent; Adult; Androsterone; Diabetes Complications; Diabetes Mell | 2013 |
Effects of low dose metformin in adolescents with type I diabetes mellitus: a randomized, double-blinded placebo-controlled study.
Topics: Adolescent; Diabetes Mellitus, Type 1; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Ins | 2015 |
A Randomized, Double-Blind, Placebo-Controlled Trial of Adjunctive Metformin Therapy in Overweight/Obese Youth with Type 1 Diabetes.
Topics: Adolescent; Adult; Blood Glucose; Chemotherapy, Adjuvant; Child; Diabetes Mellitus, Type 1; Double-B | 2015 |
Effect of Metformin Added to Insulin on Glycemic Control Among Overweight/Obese Adolescents With Type 1 Diabetes: A Randomized Clinical Trial.
Topics: Adolescent; Blood Glucose; Body Mass Index; Body Weight; Child; Diabetes Mellitus, Type 1; Double-Bl | 2015 |
Metformin improves circulating endothelial cells and endothelial progenitor cells in type 1 diabetes: MERIT study.
Topics: Adult; Biomarkers; Blood Glucose; Cell Adhesion; Cell Count; Cells, Cultured; Colony-Forming Units A | 2016 |
Association between adjunctive metformin therapy in young type 1 diabetes patients with excess body fat and reduction of carotid intima-media thickness.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adult; Carotid Artery, Common; Carotid Intima-Media | 2016 |
Novel hepato-preferential basal insulin peglispro (BIL) does not differentially affect insulin sensitivity compared with insulin glargine in patients with type 1 and type 2 diabetes.
Topics: Adult; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Fema | 2017 |
Metformin in adults with type 1 diabetes: Design and methods of REducing with MetfOrmin Vascular Adverse Lesions (REMOVAL): An international multicentre trial.
Topics: Adult; Atherosclerosis; Blood Glucose; Body Weight; Carotid Intima-Media Thickness; Cholesterol, LDL | 2017 |
A pilot study of D-chiro-inositol plus folic acid in overweight patients with type 1 diabetes.
Topics: Adolescent; Adult; Blood Glucose; Diabetes Mellitus, Type 1; Female; Folic Acid; Humans; Inositol; I | 2017 |
Effect of Metformin Therapy on Serum Fetuin Levels in Insulin Resistant Type 1 Diabetics.
Topics: Adolescent; Adult; Blood Glucose; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Fetuins; Hum | 2018 |
Effect of adjunct metformin treatment in patients with type-1 diabetes and persistent inadequate glycaemic control. A randomized study.
Topics: Adult; Blood Glucose; Body Weight; Diabetes Mellitus, Type 1; Female; Glycated Hemoglobin; Humans; H | 2008 |
The effect of metformin in overweight patients with type 1 diabetes and poor metabolic control.
Topics: Adolescent; Adult; Blood Glucose; Diabetes Mellitus, Type 1; Double-Blind Method; Female; Glycated H | 2009 |
Effect of adjunct metformin treatment on levels of plasma lipids in patients with type 1 diabetes.
Topics: Adult; Cholesterol; Diabetes Mellitus, Type 1; Female; Glycated Hemoglobin; Humans; Hypoglycemic Age | 2009 |
Pioglitazone may accelerate disease course of slowly progressive type 1 diabetes.
Topics: Adult; Age of Onset; Diabetes Mellitus, Type 1; Disease Progression; Female; Glycated Hemoglobin; Hu | 2011 |
Metformin improves endothelial function in type 1 diabetic subjects: a pilot, placebo-controlled randomized study.
Topics: Adult; Biomarkers; Blood Glucose; Brachial Artery; Diabetes Mellitus, Type 1; Dinoprost; Double-Blin | 2013 |
The benefits of metformin therapy during continuous subcutaneous insulin infusion treatment of type 1 diabetic patients.
Topics: Adult; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 1; Dose-Response Relationship, Drug; Double | 2002 |
Metformin as an adjunct therapy in adolescents with type 1 diabetes and insulin resistance: a randomized controlled trial.
Topics: Adolescent; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Female; Glucose Tolerance Test; Gl | 2003 |
Metformin and insulin in type 1 diabetes: the first step.
Topics: Diabetes Mellitus, Type 1; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Metformi | 2003 |
Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones.
Topics: Acute Disease; Adult; Aged; Arteriosclerosis; Body Mass Index; CD40 Ligand; Chromans; Chronic Diseas | 2003 |
Metformin as additional therapy in adolescents with poorly controlled type 1 diabetes: randomised placebo-controlled trial with aspects on insulin sensitivity.
Topics: Adolescent; Adult; Blood Glucose; Body Composition; Diabetes Mellitus, Type 1; Double-Blind Method; | 2003 |
Metformin as additional therapy in adolescents with poorly controlled type 1 diabetes: randomised placebo-controlled trial with aspects on insulin sensitivity.
Topics: Adolescent; Adult; Blood Glucose; Body Composition; Diabetes Mellitus, Type 1; Double-Blind Method; | 2003 |
Metformin as additional therapy in adolescents with poorly controlled type 1 diabetes: randomised placebo-controlled trial with aspects on insulin sensitivity.
Topics: Adolescent; Adult; Blood Glucose; Body Composition; Diabetes Mellitus, Type 1; Double-Blind Method; | 2003 |
Metformin as additional therapy in adolescents with poorly controlled type 1 diabetes: randomised placebo-controlled trial with aspects on insulin sensitivity.
Topics: Adolescent; Adult; Blood Glucose; Body Composition; Diabetes Mellitus, Type 1; Double-Blind Method; | 2003 |
The effect of metformin on blood glucose control in overweight patients with Type 1 diabetes.
Topics: Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 1; Double-Blind Method; Female; Glycated | 2006 |
The addition of metformin in type 1 diabetes improves insulin sensitivity, diabetic control, body composition and patient well-being.
Topics: Adolescent; Adult; Body Composition; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Humans; H | 2007 |
[Metformin in the treatment of type 1 diabetics--a placebo controlled study].
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Glycate | 2001 |
Studies on juvenile--type diabetes in children. Assessment of control under treatment with constant and variable doses of insulin with or without addition of biguanides.
Topics: Adolescent; Blood Glucose; Child; Child, Preschool; Cholesterol; Diabetes Mellitus, Type 1; Dose-Res | 1975 |
Effects of metformin treatment on erythrocyte insulin binding in normal weight subjects, in obese non diabetic subjects, in type 1 and type 2 diabetic patients.
Topics: Adult; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Doubl | 1986 |
Metformin improved insulin resistance in type I, insulin-dependent, diabetic patients.
Topics: Adolescent; Adult; Diabetes Mellitus, Type 1; Female; Humans; Insulin Infusion Systems; Insulin Resi | 1985 |
124 other studies available for metformin and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
Clinical profiling and screening for HNF4α and GCK gene mutations in Kashmiri patients with maturity-onset diabetes of the young (MODY).
Topics: Case-Control Studies; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glucokinase; Glycated He | 2022 |
Diabetic ketoacidosis as first presentation of latent autoimmune diabetes in adults in a patient with hashitoxicosis as first presentation of Hashimoto's thyroiditis: a case report.
Topics: Adult; Autoantibodies; Diabetes Mellitus, Type 1; Diabetic Ketoacidosis; Hashimoto Disease; Humans; | 2022 |
The Protective Action of Metformin against Pro-Inflammatory Cytokine-Induced Human Islet Cell Damage and the Mechanisms Involved.
Topics: Caspase 3; Cytokines; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glucose; Humans; Insulin | 2022 |
Metformin improves neurobehavioral impairments of streptozotocin-treated and western diet-fed mice: Beyond glucose-lowering effects.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitu | 2023 |
Risk factors for COVID-19 case fatality rate in people with type 1 and type 2 diabetes mellitus: A nationwide retrospective cohort study of 235,248 patients in the Russian Federation.
Topics: Aged; Coronavirus; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type 1; Diabetes Mellitus, T | 2022 |
Diabetes duration and types of diabetes treatment in data-driven clusters of patients with diabetes.
Topics: Diabetes Mellitus, Type 1; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Insulin; Ins | 2022 |
Diabetes duration and types of diabetes treatment in data-driven clusters of patients with diabetes.
Topics: Diabetes Mellitus, Type 1; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Insulin; Ins | 2022 |
Diabetes duration and types of diabetes treatment in data-driven clusters of patients with diabetes.
Topics: Diabetes Mellitus, Type 1; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Insulin; Ins | 2022 |
Diabetes duration and types of diabetes treatment in data-driven clusters of patients with diabetes.
Topics: Diabetes Mellitus, Type 1; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Insulin; Ins | 2022 |
Neuromodulatory effect of the combination of metformin and vitamin D
Topics: 5'-Nucleotidase; Adenosine; Animals; Cholecalciferol; Diabetes Mellitus, Type 1; Metformin; Rats | 2023 |
Bacille Calmette Guerin (BCG) and prevention of types 1 and 2 diabetes: Results of two observational studies.
Topics: Adult; BCG Vaccine; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glycated He | 2023 |
Baseline leptin predicts response to metformin in adolescents with type 1 diabetes and increased body mass index.
Topics: Adolescent; Body Mass Index; Diabetes Mellitus, Type 1; Humans; Hypoglycemic Agents; Insulin; Insuli | 2023 |
Influence of rutin and its combination with metformin on vascular functions in type 1 diabetes.
Topics: Acetylcholine; Animals; Blood Glucose; Cholesterol; Diabetes Mellitus, Experimental; Diabetes Mellit | 2023 |
Decoding of miR-7-5p in Colony Forming Unit-Hill Colonies as a Biomarker of Subclinical Cardiovascular Disease-A MERIT Study.
Topics: Animals; Biomarkers; Cardiovascular Diseases; Diabetes Mellitus, Type 1; Metformin; Mice; MicroRNAs | 2023 |
Diabetes, metformin and cancer risk in myotonic dystrophy type I.
Topics: Adolescent; Adult; Case-Control Studies; Child; Child, Preschool; Diabetes Mellitus, Type 1; Female; | 2020 |
Vitamin B12 and Folate Concentrations in Recent-onset Type 2 Diabetes and the Effect of Metformin Treatment.
Topics: Adolescent; Adult; Aged; Biomarkers; Blood Glucose; Cross-Sectional Studies; Diabetes Mellitus, Type | 2020 |
Evaluation of hepatic CYP2D1 activity and hepatic clearance in type I and type II diabetic rat models, before and after treatment with insulin and metformin.
Topics: Animals; Cytochrome P450 Family 2; Dextromethorphan; Diabetes Mellitus, Experimental; Diabetes Melli | 2020 |
Sodium-Glucose Cotransporter 2 Inhibitors in the Era of COVID-19 Pandemic: Is the Benefit to Risk Ratio Still Favorable?
Topics: Betacoronavirus; Cardiovascular Diseases; Coronavirus Infections; COVID-19; Cytokines; Diabetes Mell | 2020 |
Metformin Decreases Insulin Resistance in Type 1 Diabetes Through Regulating p53 and RAP2A in vitro and in vivo.
Topics: 3T3-L1 Cells; Animals; Diabetes Mellitus, Type 1; Female; Humans; Hypoglycemic Agents; Insulin Resis | 2020 |
Polyherbal mixture ameliorates hyperglycemia, hyperlipidemia and histopathological changes of pancreas, kidney and liver in a rat model of type 1 diabetes.
Topics: Animals; Antioxidants; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Fe | 2021 |
Neopterin and biopterin levels and tryptophan degradation in patients with diabetes.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biopterins; Diabetes Mellitus, Type 1; Diabetes Mellitus | 2020 |
Glucose-lowering effects of 7-day treatment with SGLT2 inhibitor confirmed by intermittently scanned continuous glucose monitoring in outpatients with type 1 diabetes. A pilot study.
Topics: Adult; Ambulatory Care; Benzhydryl Compounds; Blood Glucose; Blood Glucose Self-Monitoring; Diabetes | 2021 |
High Throughput Study for Molecular Mechanism of Metformin Pre-Diabetic Protection via Microarray Approach.
Topics: Animals; Chemoprevention; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Gene Expressio | 2022 |
Combination therapy in recent-onset type 1 diabetes.
Topics: Adult; Diabetes Mellitus, Type 1; Double-Blind Method; Humans; Hypoglycemic Agents; Liraglutide; Met | 2021 |
Initial treatment of diabetes in Italy. A nationwide population-based study from of the ARNO Diabetes Observatory.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers; Blood Glucose; Child; Child, Preschool; Data | 2021 |
Trajectories in glycated hemoglobin and body mass index in children and adolescents with diabetes using the common data model.
Topics: Adolescent; Body Mass Index; Child; Child, Preschool; Common Data Elements; Diabetes Mellitus, Type | 2021 |
Severe Complication of Diabetic Ketoacidosis and Metformin Intoxication: Bilateral Leg Amputation.
Topics: Amputation, Surgical; Diabetes Mellitus, Type 1; Diabetic Ketoacidosis; Humans; Leg; Metformin | 2021 |
Glucose-lowering drug use and new-onset atrial fibrillation in patients with diabetes mellitus.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; | 2021 |
Metformin as add-on to intensive insulin therapy in type 1 diabetes mellitus.
Topics: Adult; Aged; Blood Glucose; Cross-Sectional Studies; Diabetes Mellitus, Type 1; Dose-Response Relati | 2017 |
Predicting the 6-month risk of severe hypoglycemia among adults with diabetes: Development and external validation of a prediction model.
Topics: Aged; Cohort Studies; Colorado; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Electronic Hea | 2017 |
Metformin in type 1 diabetes.
Topics: Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin | 2017 |
Treatment of Type 1 Diabetes: Synopsis of the 2017 American Diabetes Association Standards of Medical Care in Diabetes.
Topics: Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 1; Glycated Hemoglobin; Humans | 2017 |
Type 2 Diabetes Mellitus in Adolescents: Should We Reconsider Screening?
Topics: Adolescent; Child; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Humans; Mass Screening; Met | 2018 |
The effects of metformin in type 1 diabetes mellitus.
Topics: Adult; Biomarkers; Blood Glucose; Body Weight; C-Peptide; Case-Control Studies; Diabetes Mellitus, T | 2018 |
AMPKα inactivation destabilizes atherosclerotic plaque in streptozotocin-induced diabetic mice through AP-2α/miRNA-124 axis.
Topics: AMP-Activated Protein Kinases; Animals; Collagen Type I; Collagen Type II; Diabetes Mellitus, Experi | 2018 |
Second-generation antipsychotic and diabetes mellitus in children and adolescents.
Topics: Adolescent; Antipsychotic Agents; Autistic Disorder; Benzodiazepines; Blood Glucose; Clomipramine; D | 2017 |
Type 1 diabetes care: Improvement by standardization in a diabetes rehabilitation clinic. An observational report.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 1; Female; Glycated Hemoglobin; Humans; Hypoglycemic A | 2018 |
Increased Micronuclei Frequency in Oral and Lingual Epithelium of Treated Diabetes Mellitus Patients.
Topics: Cheek; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; DNA Damage; Epithelium; Female; Humans; | 2018 |
Metabolomic analysis and biochemical changes in the urine and serum of streptozotocin-induced normal- and obese-diabetic rats.
Topics: Amino Acids; Animals; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Experime | 2018 |
A new experience for incorrect insulin administration.
Topics: Diabetes Mellitus, Type 1; Dose-Response Relationship, Drug; Glycated Hemoglobin; Humans; Hypoglycem | 2018 |
Acquired generalised lipodystrophy and type 1 diabetes mellitus in a child: a rare and implacable association.
Topics: Anticholesteremic Agents; Child; Diabetes Mellitus, Type 1; Humans; Hypoglycemic Agents; Insulin; In | 2018 |
The effects of safranal, a constitute of saffron, and metformin on spatial learning and memory impairments in type-1 diabetic rats: behavioral and hippocampal histopathological and biochemical evaluations.
Topics: Animals; Behavior, Animal; Caspase 3; Cell Count; Crocus; Cyclohexenes; Diabetes Mellitus, Experimen | 2018 |
Medicines for Treatment Intensification in Type 2 Diabetes and Type of Insulin in Type 1 and Type 2 Diabetes in Low-Resource Settings: Synopsis of the World Health Organization Guidelines on Second- and Third-Line Medicines and Type of Insulin for the Con
Topics: Adult; Blood Glucose; Contraindications, Drug; Developed Countries; Developing Countries; Diabetes M | 2018 |
Anti-Angiogenic miR-222, miR-195, and miR-21a Plasma Levels in T1DM Are Improved by Metformin Therapy, Thus Elucidating Its Cardioprotective Effect: The MERIT Study.
Topics: Adult; Biomarkers; Case-Control Studies; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Endotheli | 2018 |
THE CIRCLE OF CARE IN DIABETES: FROM HOME TO HOSPITAL TO HOME.
Topics: Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Humans; Metformin; Patient Discharge; Sitaglip | 2018 |
Curcumin augments the cardioprotective effect of metformin in an experimental model of type I diabetes mellitus; Impact of Nrf2/HO-1 and JAK/STAT pathways.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cardiotonic Agents; Curcumin; Diabetes Mellitus, E | 2019 |
An Irish National Diabetes in Pregnancy Audit: aiming for best outcomes for women with diabetes.
Topics: Abortion, Spontaneous; Adult; Aspirin; Cesarean Section; Clinical Audit; Delivery of Health Care; De | 2020 |
Chronic diarrhea: an unusual clinical presentation of vitamin B
Topics: Diabetes Mellitus, Type 1; Diarrhea; Humans; Male; Metformin; Middle Aged; Vitamin B 12; Vitamin B 1 | 2019 |
Effect of metformin on clinical and biochemical hyperandrogenism in adolescent girls with type 1 diabetes.
Topics: Adolescent; Adult; Biomarkers; Child; Diabetes Mellitus, Type 1; Female; Follow-Up Studies; Humans; | 2019 |
Metformin mitigates impaired testicular lactate transport/utilisation and improves sexual behaviour in streptozotocin-induced diabetic rats.
Topics: Animals; Biological Transport; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Glucose T | 2021 |
A case of hepatocyte nuclear factor-1β (TCF2) maturity onset diabetes of the young misdiagnosed as type 1 diabetes and treated unnecessarily with insulin.
Topics: Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnostic Errors; Female; Hepatocyte Nuclear | 2013 |
Slowly progressive type 1 diabetes treated with metformin for five years after onset.
Topics: Autoantibodies; Autoantigens; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 1; Disease Progressi | 2013 |
Effects of two weeks of metformin treatment on whole-body glycocalyx barrier properties in db/db mice.
Topics: Animals; Blood Glucose; Capillary Permeability; Diabetes Mellitus, Type 1; Disease Models, Animal; E | 2013 |
Effective assessment of diabetes control using personal glucometers (CONTOURLINK, Bayer, Germany; CALLA, Wellion, Austria; LINUS, Agamatrix, USA).
Topics: Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; | 2013 |
[Difficult diagnosis in a 17-year-old patient: Type 1 diabetes? Type 2 diabetes? Or "double diabetes"?].
Topics: Adolescent; Autoantibodies; Blood Glucose; C-Peptide; Cation Transport Proteins; Comorbidity; Diabet | 2014 |
Effect of vitamin D3 on behavioural and biochemical parameters in diabetes type 1-induced rats.
Topics: Acetylcholinesterase; Animals; Blood Glucose; Body Weight; Cerebral Cortex; Cholecalciferol; Diabete | 2014 |
Can genetics improve precision of therapy in diabetes?
Topics: Biological Availability; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase | 2014 |
Current use of metformin in addition to insulin in pediatric patients with type 1 diabetes mellitus: an analysis based on a large diabetes registry in Germany and Austria.
Topics: Adolescent; Austria; Body Mass Index; Child; Cohort Studies; Diabetes Mellitus, Type 1; Diabetic Ang | 2015 |
Disseminated cryptococcosis in a diabetic patient.
Topics: Administration, Oral; Antifungal Agents; Cryptococcosis; Cryptococcus neoformans; Diabetes Mellitus, | 2014 |
Association of Organic Cation Transporter 1 With Intolerance to Metformin in Type 2 Diabetes: A GoDARTS Study.
Topics: Aged; Diabetes Mellitus, Type 1; Female; Genetic Variation; Humans; Hypoglycemic Agents; Male; Metfo | 2015 |
Association of Organic Cation Transporter 1 With Intolerance to Metformin in Type 2 Diabetes: A GoDARTS Study.
Topics: Aged; Diabetes Mellitus, Type 1; Female; Genetic Variation; Humans; Hypoglycemic Agents; Male; Metfo | 2015 |
Association of Organic Cation Transporter 1 With Intolerance to Metformin in Type 2 Diabetes: A GoDARTS Study.
Topics: Aged; Diabetes Mellitus, Type 1; Female; Genetic Variation; Humans; Hypoglycemic Agents; Male; Metfo | 2015 |
Association of Organic Cation Transporter 1 With Intolerance to Metformin in Type 2 Diabetes: A GoDARTS Study.
Topics: Aged; Diabetes Mellitus, Type 1; Female; Genetic Variation; Humans; Hypoglycemic Agents; Male; Metfo | 2015 |
(7) Approaches to glycemic treatment.
Topics: Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibit | 2015 |
Young at heart. Could metformin help type 1 teens avoid heart disease as adults?
Topics: Adolescent; Adult; Diabetes Mellitus, Type 1; Heart Diseases; Humans; Hypoglycemic Agents; Metformin | 2014 |
Vitamin D₃ prevents the increase in ectonucleotidase activities and ameliorates lipid profile in type 1 diabetic rats.
Topics: 5'-Nucleotidase; Adenosine Deaminase; Adenosine Triphosphatases; Animals; Blood Platelets; Cholecalc | 2015 |
The skin remodeling in type 1 diabetes and insulin resistance animal models.
Topics: Animals; Collagen Type III; Connective Tissue; Diabetes Mellitus, Type 1; Insulin; Insulin Resistanc | 2015 |
New Insight Into Metformin Action: Regulation of ChREBP and FOXO1 Activities in Endothelial Cells.
Topics: Adenylate Kinase; Animals; Aorta; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Carri | 2015 |
Metformin and Myocardial Injury in Patients With Diabetes and ST-Segment Elevation Myocardial Infarction: A Propensity Score Matched Analysis.
Topics: Academic Medical Centers; Biomarkers; Chi-Square Distribution; Creatine Kinase, MB Form; Diabetes Me | 2015 |
Metformin in obese teenagers does not improve glycaemic control, study finds.
Topics: Diabetes Mellitus, Type 1; Female; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Obesity | 2015 |
Mortality in Individuals Treated With Glucose-Lowering Agents: A Large, Controlled Cohort Study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Belgium; Cardiovascular Diseases; Cohort Studies; Diabe | 2016 |
A case of lean polycystic ovary syndrome with early stage of type 1 diabetes successfully treated with metformin.
Topics: Adult; Diabetes Mellitus, Type 1; Disease Progression; Female; Humans; Hypoglycemic Agents; Metformi | 2016 |
Presence of type 1 diabetes in women with polycystic ovary syndrome: Does it have any impact on anti-Müllerian hormone concentrations?
Topics: Anti-Mullerian Hormone; Biomarkers; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Female; Hu | 2016 |
Metformin improves the angiogenic functions of endothelial progenitor cells via activating AMPK/eNOS pathway in diabetic mice.
Topics: AMP-Activated Protein Kinases; Animals; Cell Movement; Cells, Cultured; Diabetes Mellitus, Experimen | 2016 |
The prevalence and treatment patterns of diabetes in the Greek population based on real-world data from the nation-wide prescription database.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type | 2016 |
Metformin reduces weight gain in overweight/obese adolescents with type 1 diabetes.
Topics: Adolescent; Diabetes Mellitus, Type 1; Humans; Hypoglycemic Agents; Metformin; Obesity; Weight Gain | 2016 |
Metformin in type 1 diabetes mellitus? Revisiting treatment dogmas in diabetes.
Topics: Diabetes Mellitus, Type 1; Humans; Hypoglycemic Agents; Metformin | 2016 |
Different effects of basal insulin peglispro and insulin glargine on liver enzymes and liver fat content in patients with type 1 and type 2 diabetes.
Topics: Adipose Tissue; Adult; Aged; Alanine Transaminase; Aspartate Aminotransferases; Bilirubin; Blood Glu | 2016 |
Metformin with insulin does not improve the glycaemic control of overweight/obese adolescents with type 1 diabetes.
Topics: Adolescent; Blood Glucose; Diabetes Mellitus, Type 1; Humans; Hypoglycemic Agents; Insulin; Metformi | 2017 |
Metformin-induced encephalopathy without lactic acidosis in a patient with contraindication for metformin.
Topics: Acidosis, Lactic; Brain Diseases; Contraindications; Diabetes Mellitus, Type 1; Diabetic Nephropathi | 2009 |
Sulphonyurea as a cause of severe hypoglycaemia in the community.
Topics: Adult; Aged; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Huma | 2010 |
Glucose supply and insulin demand dynamics of antidiabetic agents.
Topics: 1-Deoxynojirimycin; Acarbose; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Ty | 2010 |
Metformin in type 1 diabetes reduces insulin requirements without significantly improving glycaemic control.
Topics: Diabetes Mellitus, Type 1; Humans; Hypoglycemic Agents; Insulin; Metformin | 2010 |
[Effect of initial periodontal therapy on diabetic patients with chronic periodontitis].
Topics: Adult; Alveolar Bone Loss; Blood Glucose; Chronic Periodontitis; Dental Scaling; Diabetes Mellitus, | 2010 |
Metformin can activate imidazoline I-2 receptors to lower plasma glucose in type 1-like diabetic rats.
Topics: Animals; beta-Endorphin; Blood Glucose; Diabetes Mellitus, Type 1; Disease Models, Animal; Humans; H | 2011 |
Metformin in type 1 diabetes reduces insulin requirements without significantly improving glycaemic control. Reply to Schatz H [letter].
Topics: Diabetes Mellitus, Type 1; Humans; Hypoglycemic Agents; Insulin; Metformin | 2011 |
Transient vision loss in a patient with severe metformin-associated lactic acidosis.
Topics: Acidosis, Lactic; Acute Disease; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Humans; Hypoglyc | 2012 |
Could there be a role for metformin in type 1 and type 2 diabetic pregnancies?
Topics: Diabetes Mellitus, Type 1; Humans; Metformin | 2011 |
Altered redox homeostasis in human diabetes saliva.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Age Factors; Biomarkers; Deoxyguanosine; Diabetes Mellitus, Type 1; Dia | 2012 |
Pregnancy management of women with pregestational diabetes.
Topics: Congenital Abnormalities; Counseling; Diabetes Complications; Diabetes Mellitus, Type 1; Diabetes Me | 2011 |
Ketosis-prone type 2 diabetes mellitus in a patient with Sheehan's syndrome: a rare convergence of two distinct endocrine entities.
Topics: Adult; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Hypogl | 2012 |
Obestatin induced recovery of myocardial dysfunction in type 1 diabetic rats: underlying mechanisms.
Topics: AMP-Activated Protein Kinases; Animals; Blotting, Western; Cardiotonic Agents; Cell Line; Diabetes M | 2012 |
Lactic acidosis in patients with diabetes.
Topics: Acidosis, Lactic; Adult; Aged; Aged, 80 and over; Alcohol Drinking; Alcoholism; Diabetes Mellitus, T | 2013 |
Seeking sweet relief for diabetes.
Topics: Behavior Control; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diet; Exe | 2002 |
[News on diabetes and public health perspectives].
Topics: Administration, Oral; Adult; Chromans; Clinical Trials as Topic; Diabetes Mellitus; Diabetes Mellitu | 2002 |
Metformin in type 1 diabetes: is this a good or bad idea?
Topics: Diabetes Mellitus, Type 1; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Hypo | 2003 |
Metformin use as an adjunct to insulin treatment.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Humans; Hypoglycemic Age | 2003 |
Safety issues on metformin use.
Topics: Diabetes Mellitus, Type 1; Humans; Hypoglycemic Agents; Metformin; Safety | 2003 |
Case 25-2004: a woman with severe obesity, diabetes, and hypertension.
Topics: Diabetes Mellitus, Type 1; Female; Gastric Bypass; Humans; Hypoglycemic Agents; Metformin; Obesity, | 2004 |
[Short-term and long-term effect of metformin in type 1 diabetics].
Topics: Adult; Body Weight; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Follow-Up Studies; Humans; | 2001 |
Usefulness of the addition of metformin to insulin in pediatric patients with type 1 diabetes mellitus.
Topics: Adolescent; Adult; Body Mass Index; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Female; Gl | 2005 |
Oral agents in managing diabetes mellitus in children and adolescents.
Topics: Administration, Oral; Adolescent; Carbamates; Child; Clinical Trials as Topic; Diabetes Mellitus, Ty | 2005 |
Mitochondrial dysfunction as the cause of the failure to precondition the diabetic human myocardium.
Topics: Adenosine; Adrenergic alpha-Agonists; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitu | 2006 |
Willingness to pay for inhaled insulin: a contingent valuation approach.
Topics: Administration, Inhalation; Administration, Oral; Adult; Canada; Diabetes Mellitus, Type 1; Diabetes | 2005 |
A role for AMP-activated protein kinase in diabetes-induced renal hypertrophy.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Animals; Carrier Proteins; Cells, Culture | 2007 |
Thiazolidinediones may not reduce diabetes incidence in type 1 diabetes.
Topics: Animals; Cyclophosphamide; Cytokines; Diabetes Mellitus, Type 1; Disease Progression; Female; Immuno | 2006 |
Utilization of diabetes medication and cost of testing supplies in Saskatchewan, 2001.
Topics: Adult; Aged; Algorithms; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Drug Costs; Drug Moni | 2006 |
[Classic drug in diabetes therapy. Revise contraindications?].
Topics: Acidosis, Lactic; Adult; Child; Contraindications; Diabetes Mellitus, Type 1; Diabetes Mellitus, Typ | 2007 |
Insulin requirement for the antihyperglycaemic effect of metformin.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 1; Glucose; Glucose Tolerance Test; Hyperglycemia; I | 1994 |
Regulation of glucose transport and expression of GLUT3 transporters in human circulating mononuclear cells: studies in cells from insulin-dependent diabetic and nondiabetic individuals.
Topics: Adolescent; Adult; Biological Transport; Blotting, Northern; Diabetes Mellitus, Type 1; Female; Gluc | 1994 |
Metformin ameliorates diabetes but does not normalize the decreased GLUT 4 content in skeletal muscle of obese (fa/fa) Zucker rats.
Topics: Animals; Biomarkers; Blood Glucose; Cell Membrane; Diabetes Mellitus; Diabetes Mellitus, Type 1; Fru | 1993 |
Conference report: renal disease, metformin, and the adipocyte.
Topics: Adipocytes; Animals; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabet | 1996 |
Metformin-associated nonketotic metabolic acidosis.
Topics: Acidosis, Lactic; Acute Kidney Injury; Aged; Diabetes Mellitus, Type 1; Humans; Hypoglycemic Agents; | 1997 |
[Insulin resistance, hypertension and diabetes--value of Metformin and ACE-inhibitors].
Topics: Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Huma | 1994 |
Metformin does not alter diabetes incidence in the NOD mouse.
Topics: Aging; Animals; Blood Glucose; Diabetes Mellitus, Type 1; Female; Glycosuria; Hypoglycemic Agents; I | 1997 |
Clinical problem-solving. The importance of a name.
Topics: Acanthosis Nigricans; Adolescent; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, T | 1999 |
Administration of metformin to a diabetic woman with extreme hyperandrogenemia of nontumoral origin: management of infertility and prevention of inadvertent masculinization of a female fetus.
Topics: Adult; Diabetes Mellitus, Type 1; Disorders of Sex Development; Female; Humans; Hyperandrogenism; Hy | 1999 |
The prevalence of chronic diarrhea among diabetic patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care Facilities; Autonomic Nervous System Dis | 1999 |
Diabetes prevention.
Topics: Blood Glucose; Diabetes Mellitus, Type 1; Humans; Hypoglycemic Agents; Metformin | 2002 |
Diabetes prevention.
Topics: Diabetes Mellitus; Diabetes Mellitus, Type 1; Humans; Hypoglycemic Agents; Insulin Resistance; Metfo | 2002 |
Diabetes prevention.
Topics: Child; Diabetes Mellitus, Type 1; Eligibility Determination; Humans; Hypoglycemic Agents; Life Style | 2002 |
Effects of metformin on haemorheology, lipid parameters and insulin resistance in insulin-dependent diabetic patients (IDDM).
Topics: Diabetes Mellitus, Type 1; Female; Humans; Insulin Resistance; Lipids; Male; Metformin; Rheology | 1991 |
Erythrocyte glucose consumption in insulin-dependent diabetes: effect of metformin in vitro.
Topics: Blood Glucose; Diabetes Mellitus, Type 1; Erythrocytes; Humans; In Vitro Techniques; Metformin; Refe | 1991 |
Study of the effect of metformin on platelet aggregation in insulin-dependent diabetics.
Topics: Adult; Blood Glucose; Cholesterol; Diabetes Mellitus, Type 1; Fibrinogen; Glycated Hemoglobin; Human | 1989 |
[Remission of insulin-dependent diabetes (IDD). Insulin requirements of non-insulin-dependent diabetes (NIDD). The role of oral antidiabetics and the value of metformin].
Topics: Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Remiss | 1986 |
Serum lipids and lipoproteins in middle-aged non-insulin-dependent diabetics.
Topics: Cholesterol; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diet, Diabetic; Female; Humans; H | 1985 |
[Value of metformin-insulin association in the treatment of insulin- dependent diabetes].
Topics: Diabetes Mellitus, Type 1; Humans; Insulin; Metformin | 1985 |
Mild familial diabetes with dominant inheritance.
Topics: Acetohexamide; Adolescent; Adult; Aged; Blood Glucose; Carbohydrates; Child; Chlorpropamide; Diabete | 1974 |
[Exogenous steroid diabetes in a leukemic boy. Study of insulin and GH blood levels].
Topics: Blood Glucose; Child; Diabetes Mellitus, Type 1; Fatty Acids, Nonesterified; Glucose Tolerance Test; | 1973 |
[On the clinical use of biguanides].
Topics: Aged; Biguanides; Blood Glucose; Body Weight; Cholesterol; Depression, Chemical; Diabetes Mellitus; | 1969 |